{"gene":"NFATC1","run_date":"2026-04-29T11:37:56","timeline":{"discoveries":[{"year":2002,"finding":"RANKL selectively induces NFATc1 expression via TRAF6 and c-Fos signaling pathways, and RANKL-evoked Ca2+ oscillations lead to calcineurin-mediated activation (dephosphorylation) of NFATc1, triggering a sustained NFATc1-dependent transcriptional program during osteoclast differentiation. NFATc1-deficient embryonic stem cells fail to differentiate into osteoclasts, and ectopic NFATc1 expression drives osteoclastogenesis without RANKL, establishing NFATc1 as the master transcriptional switch downstream of RANKL.","method":"Genetic knockout (NFATc1-/- ES cells), retroviral ectopic expression, Ca2+ oscillation imaging, calcineurin inhibitor studies","journal":"Developmental Cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (KO, overexpression, signaling pathway analysis), replicated across subsequent studies","pmids":["12479813"],"is_preprint":false},{"year":1997,"finding":"Glycogen synthase kinase-3 (GSK-3) phosphorylates conserved serine residues in the N-terminus of NFATc1, promoting nuclear export and opposing Ca2+-calcineurin-mediated nuclear import. GSK-3 was purified as the NFATc1 kinase (together with a priming kinase activity) and shown to directly phosphorylate NFATc1 conserved serines required for nuclear export.","method":"Biochemical purification of NFATc1 kinase activity, in vitro phosphorylation assay, nuclear localization studies","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase reconstitution with biochemical purification; foundational paper with >600 citations","pmids":["9072970"],"is_preprint":false},{"year":1998,"finding":"NFATc1 is essential for cardiac valve formation (aortic and pulmonary valves); it is expressed specifically in cardiac endothelial cells and its nuclear translocation in endocardial cells is controlled by calcineurin, as demonstrated by cyclosporin A treatment retaining NFATc1 in the cytoplasm of normal embryos.","method":"Targeted gene disruption (knockout mice), calcineurin inhibitor (cyclosporin A) treatment, immunolocalization in cardiac endothelial cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with defined cardiac phenotype plus pharmacological calcineurin inhibition; >470 citations","pmids":["9515964"],"is_preprint":false},{"year":1998,"finding":"Solution NMR structure of the binary NFATC1 DNA-binding domain (DBD) complexed with the ARRE2 DNA site from the IL-2 promoter reveals that DNA binding induces folding of structural elements required for sequence-specific recognition and cooperative protein-protein contacts; the orientation of NFAT DBD in the binary complex differs from that in the ternary NFATC2/AP-1/DNA complex, indicating domain reorientation upon formation of a cooperative transcriptional complex.","method":"NMR solution structure determination","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — NMR structure of the core DBD-DNA complex with functional interpretation","pmids":["9506523"],"is_preprint":false},{"year":2000,"finding":"GSK-3 inhibits the intrinsic DNA-binding activity of NFATc1 by phosphorylating the conserved Ser-Pro repeat motifs; calcineurin dephosphorylation enhances DNA binding, while in vitro phosphorylation of NFATc1 by GSK-3 inhibits its ability to bind DNA, demonstrating regulation at the level of DNA-binding activity in addition to subcellular localization.","method":"Gel mobility shift assay (EMSA), in vitro phosphorylation, calcineurin activation in cells, NFATc1 Ser-Pro repeat mutant analysis","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical assays with mutant analysis and cell-based validation","pmids":["11063740"],"is_preprint":false},{"year":2000,"finding":"JNK, ERK, p38, and CK2 physically associate with the NFATc1 N-terminal regulatory domain, directly phosphorylate Ser172 and the conserved Ser-Pro repeats to regulate nuclear localization, and overexpression of JNK, ERK, or p38 blocks ionomycin-induced NFATc1 nuclear translocation. CK2 also binds the N-terminus and phosphorylates a conserved motif downstream of Ser-Pro repeats important for nuclear export.","method":"Co-immunoprecipitation, in vitro kinase assays, subcellular localization studies, overexpression and pharmacological inhibition of kinases","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding and direct phosphorylation with functional localization readout, multiple kinases tested","pmids":["10652349"],"is_preprint":false},{"year":2005,"finding":"NFATc1 autoregulates its own expression through its P1 promoter (within a CpG island): NFATc1 binds tandemly arranged NFAT sites in its own promoter to sustain high-level expression selectively in osteoclasts in vivo. This autoregulatory loop explains why NFATc2 can rescue osteoclastogenesis in vitro but not in vivo, since NFATc1 autoregulation at the epigenetic level is uniquely required for cell-lineage commitment.","method":"Adoptive transfer of NFATc1-/- hematopoietic stem cells, blastocyst complementation, retroviral rescue, promoter analysis (ChIP, reporter assays), NFATc1 ectopic expression","journal":"Journal of Experimental Medicine","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic rescue combined with promoter/epigenetic mechanistic studies; >700 citations","pmids":["16275763"],"is_preprint":false},{"year":2001,"finding":"NFATc1 undergoes activity-dependent, calcineurin-sensitive nuclear translocation in adult skeletal muscle fibers specifically in response to slow-twitch (10 Hz continuous or 10 Hz trains) but not fast-twitch stimulation patterns, contributing to slow-twitch fiber type-specific gene expression. Constitutively active NFATc1(S→A) shows a distinct intranuclear foci pattern in unstimulated fibers.","method":"GFP-fusion protein live imaging in cultured adult mouse skeletal muscle fibers, electrical stimulation with defined patterns, cyclosporin A (calcineurin inhibitor) treatment","journal":"Journal of Cell Biology","confidence":"High","confidence_rationale":"Tier 2 — live cell imaging with functional stimulation parameters and pharmacological validation","pmids":["11581284"],"is_preprint":false},{"year":2002,"finding":"The short isoform NFATc1/αA is selectively induced to high levels via autoregulation of the NFATc1 P1 promoter (containing tandem NFAT binding sites within a CpG island DNase I hypersensitive site) by NFATs in effector T cells. This isoform does not promote apoptosis (unlike other NFATs), enhancing effector T cell survival. A second promoter P2 before exon 2 is not NFAT-controlled and directs longer isoforms.","method":"Promoter reporter assay, DNase I hypersensitivity mapping, NFAT binding site mutation, apoptosis assays, isoform-specific expression analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — promoter dissection with multiple methods and functional isoform characterization","pmids":["12121669"],"is_preprint":false},{"year":2008,"finding":"NFATc1 is preferentially expressed in hair follicle stem cells in their niche where it acts downstream of BMP signaling to transcriptionally repress CDK4 and maintain stem cell quiescence. Pharmacological or genetic NFATc1 ablation leads to premature stem cell activation and precocious follicular growth.","method":"Conditional and complete NFATc1 gene ablation, cyclosporin A pharmacological suppression, CDK4 reporter assays, hair follicle stem cell analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined molecular target (CDK4 repression) and phenotypic readout; >340 citations","pmids":["18243104"],"is_preprint":false},{"year":2008,"finding":"NFATc1 directly binds to a novel regulatory element at the pdcd1 (PD-1) locus to regulate PD-1 gene expression upon T cell activation; NFATc1 binding was demonstrated by ChIP assay, and mutation of the NFATc1 binding site completely abolished promoter activity.","method":"Chromatin immunoprecipitation (ChIP), luciferase reporter assay with NFATc1 binding site mutation, calcineurin inhibitor (cyclosporin A) and NFAT inhibitor treatment","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus mutagenesis of binding site with functional reporter readout","pmids":["18802087"],"is_preprint":false},{"year":2007,"finding":"During osteoclast differentiation, MITF and PU.1 form complexes at osteoclast target gene promoters (cathepsin K, acid phosphatase 5) in response to CSF-1 alone, while RANKL+CSF-1 additionally recruit p38 MAPK-phosphorylated MITF and SWI/SNF chromatin-remodeling complexes. NFATc1 is subsequently recruited to these promoter complexes during terminal differentiation to maintain target gene expression.","method":"ChIP on target gene promoters, Co-IP of transcription factor complexes, MITF/PU.1 mouse genetic models","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — ChIP and Co-IP with genetic validation in mouse models","pmids":["17403683"],"is_preprint":false},{"year":2014,"finding":"NFATc1 forms a transcriptional complex with STAT3 in pancreatic epithelial cells that promotes KrasG12D-driven carcinogenesis; NFATc1-STAT3 complexes mediate enhancer-promoter communications at jointly regulated oncogenic genes (Cyclin, EGFR, WNT family members). Genetic or pharmacologic NFATc1 ablation attenuates inflammation-induced carcinogenesis.","method":"Co-immunoprecipitation, ChIP, genetic mouse models (NFATc1 activation/ablation in KrasG12D background), pharmacological inhibition","journal":"Cancer Discovery","confidence":"High","confidence_rationale":"Tier 2 — Co-IP of NFATc1-STAT3 complex, ChIP for enhancer-promoter contacts, in vivo mouse genetic models","pmids":["24694735"],"is_preprint":false},{"year":2011,"finding":"RANKL/NFATc1 signaling in epicardium-derived cells (EPDCs) induces cathepsin K (CTSK) expression for extracellular matrix degradation and cell invasion into myocardium; conditional loss of NFATc1 in EPDCs reduces coronary vessel and fibrous matrix penetration. RANKL treatment induces Ctsk expression in PE-derived cell cultures via a calcineurin-dependent mechanism.","method":"Conditional knockout of NFATc1 in EPDCs, calcineurin inhibitor treatment, RANKL stimulation of PE-derived cell cultures, in vivo embryonic analysis","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with specific molecular target (CTSK) and in vivo phenotypic consequence","pmids":["21447555"],"is_preprint":false},{"year":2014,"finding":"STAT3 drives the transcription of NFATc1 by directly binding to its promoter in osteoclasts; STAT3-deficient bone marrow macrophages show decreased NFATc1 expression and impaired osteoclast differentiation, which is rescued by enforced NFATc1 expression.","method":"Conditional Stat3 knockout (Ctsk-Cre), ChIP for STAT3 binding to NFATc1 promoter, siRNA knockdown of STAT3, enforced NFATc1 expression rescue","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — conditional KO, ChIP, and rescue experiment with multiple orthogonal approaches","pmids":["31462535"],"is_preprint":false},{"year":2017,"finding":"DYRK1A phosphorylates NFATc1/αA at S261, S278, S403, and S409, interfering with NFATc1 ubiquitination and ubiquitin-proteasome degradation, thereby increasing NFATc1 protein stability and transcriptional activity (in contrast to its known role in destabilizing NFATc2).","method":"In vitro phosphorylation assay with site-specific mutants, ubiquitination assay, protein stability analysis","journal":"PLoS ONE","confidence":"High","confidence_rationale":"Tier 1 — in vitro phosphorylation with site-specific mutagenesis and ubiquitination functional readout","pmids":["28235034"],"is_preprint":false},{"year":2011,"finding":"DYRK1A directly inhibits NFATc1 through phosphorylation (inactivation); harmine, a DYRK1A inhibitor, promotes NFATc1 dephosphorylation/activation in osteoclast precursors. In vitro phosphorylation assay demonstrated that harmine directly inhibited DYRK1A-mediated phosphorylation of NFATc1.","method":"In vitro phosphorylation assay, harmine treatment of RAW264.7 and bone marrow macrophages, NFATc1 expression analysis","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro kinase assay, but single study with limited mutagenesis","pmids":["21504804"],"is_preprint":false},{"year":2012,"finding":"Cot kinase (Tpl-2) directly phosphorylates all Ca2+/calcineurin-regulated NFAT family members (NFATc1–NFATc4) and increases their protein stability/levels, promoting Ca2+ oscillation/calcineurin-independent osteoclastogenesis. Cot activity was enhanced by osteoblast–osteoclast cell-cell interaction.","method":"In vitro kinase assay, co-culture system, Cot overexpression/knockdown in osteoclasts, protein stability analysis","journal":"Molecular and Cellular Biology","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro phosphorylation of NFATc1 by Cot with functional validation in cell-cell interaction model","pmids":["22615493"],"is_preprint":false},{"year":2021,"finding":"SUMOylation of NFATc1 represses IL-2 production in T cells; mice with prevented NFATc1 SUMOylation show elevated IL-2, expanded Tregs, and suppressed autoreactive/alloreactive immune responses. Increased IL-2 from non-SUMOylated NFATc1 counteracts IL-17 and IFN-γ through STAT5 and Blimp-1 induction.","method":"Transgenic knock-in mouse (SUMO modification prevented), EAE and graft-versus-host disease models, cytokine profiling, signaling analysis","journal":"Journal of Experimental Medicine","confidence":"High","confidence_rationale":"Tier 2 — novel transgenic mouse with defined SUMO-site mutation and in vivo immune phenotype with mechanistic pathway analysis","pmids":["32986812"],"is_preprint":false},{"year":2015,"finding":"NFATc1 forms a complex with Sox2 to drive EMT reprogramming and maintain pancreatic cancer cells in a stem cell-like state; NFATc1-Sox2-mediated dedifferentiation is opposed by antithetical p53-miR200c signaling.","method":"Co-immunoprecipitation of NFATc1-Sox2 complex, genetic mouse models (GEMM), NFATc1 knockdown/overexpression, in vitro EMT assays","journal":"EMBO Journal","confidence":"High","confidence_rationale":"Tier 2 — Co-IP of NFATc1-Sox2 complex with GEMM validation and functional EMT assays","pmids":["25586376"],"is_preprint":false},{"year":2024,"finding":"The serine synthesis pathway (SSP)-derived α-ketoglutarate is necessary for histone demethylases that remove repressive H3K27me3 marks at the Nfatc1 gene locus, inducing NFATc1 expression and consequent osteoclast maturation. Deletion of the rate-limiting SSP enzyme phosphoglycerate dehydrogenase impairs osteoclast differentiation and increases bone mass.","method":"Conditional knockout of PHGDH in osteoclast progenitors, histone methylation ChIP at Nfatc1 locus, pharmacological PHGDH inhibition, α-ketoglutarate metabolite supplementation","journal":"Nature Metabolism","confidence":"High","confidence_rationale":"Tier 2 — conditional KO, ChIP for histone marks at Nfatc1 locus, metabolic-epigenetic mechanistic link established","pmids":["38200114"],"is_preprint":false},{"year":2018,"finding":"ASXL1 loss induces concordant reduction of inhibitory H3K27me3 and gain of H3K4me3 at the NFATc1 and itgb3 gene loci, leading to increased NFATc1 expression and enhanced osteoclastogenesis. Jmjd3 histone demethylase knockdown in ASXL1-deficient precursors restores H3K27me3 on the NFATc1 promoter and impairs osteoclast formation.","method":"Conditional ASXL1 knockout in myeloid cells, ChIP for H3K27me3/H3K4me3 at NFATc1 promoter, Jmjd3 siRNA knockdown","journal":"Blood Advances","confidence":"High","confidence_rationale":"Tier 2 — ChIP for histone modifications at NFATc1 locus, genetic rescue experiment with Jmjd3 knockdown","pmids":["30266822"],"is_preprint":false},{"year":2014,"finding":"NFATc1 regulates the expression of InsP3R2 (type 2 inositol 1,4,5-trisphosphate receptor) by directly binding to the Itpr2 promoter; calcineurin-NFATc signaling drives Itpr2 transcription in cardiomyocytes, creating a positive feedback loop between InsP3R2 and calcineurin-NFATc signaling during cardiac hypertrophy.","method":"ChIP for NFATc1 binding at Itpr2 promoter, promoter-reporter assay, cyclosporin A inhibition, calcineurin-A transgenic mice, hypertrophic agonist stimulation","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — direct ChIP of NFATc1 at Itpr2 promoter, in vivo calcineurin transgenic validation","pmids":["24415751"],"is_preprint":false},{"year":2009,"finding":"VEGF activates NFATc1 via calcineurin and MEK1-ERK1/2-dependent signaling to promote endocardial cushion cell proliferation during valve development; subsequently RANKL inhibits VEGF-induced proliferation while inducing cathepsin K via calcineurin/NFATc1 and JNK1/2-dependent signaling, demonstrating ligand-specific cofactor cooperation.","method":"NFATc1-/- mice analysis, chick ECC explant cultures, pharmacological inhibition of calcineurin/MEK/JNK, VEGF/RANKL stimulation","journal":"Circulation Research","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout combined with pharmacological pathway dissection in ex vivo explant model","pmids":["19661463"],"is_preprint":false},{"year":2017,"finding":"The cytoplasmic ITIM motif of DC-STAMP regulates NFATc1 nuclear translocation and expression; deletion of ITIM elevates Ca2+ flux amplitude/duration and alters NFATc1-dependent osteoclast phenotypes. DC-STAMP overexpression restores NFATc1 expression in DC-STAMP-/- cells.","method":"Light-activatable DC-STAMP chimeric molecule, Ca2+ flux imaging, ITIM deletion mutants, NFATc1 nuclear translocation assay, DC-STAMP overexpression","journal":"Journal of Cellular Physiology","confidence":"Medium","confidence_rationale":"Tier 2 — engineered chimeric molecule for signaling studies, but mechanistic link between ITIM and NFATc1 is partly correlative","pmids":["27723141"],"is_preprint":false},{"year":2003,"finding":"NFATc1 is required cell-intrinsically for normal B-1a cell development; NFATc1 protein is elevated ~5-fold in B-1a cells compared with B-2 cells, and the B-1a compartment is essentially absent in NFATc1-/- mice but normal in NFATc2-/- mice. Mixed-allotype chimeras and retroviral gene transduction confirmed the B cell-intrinsic requirement.","method":"NFATc1-/- and NFATc2-/- mouse analysis, mixed-allotype chimeras, retroviral NFATc1 gene transduction, flow cytometry","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — genetic KO combined with chimera and retroviral rescue experiments definitively establishing cell-intrinsic function","pmids":["14595020"],"is_preprint":false},{"year":2017,"finding":"Gα13 negatively regulates osteoclastogenesis through the RhoA/Akt/GSK3β/NFATc1 signaling pathway; Gna13-deficiency decreases RhoA activity and enhances Akt/GSK3β/NFATc1 signaling. Akt inhibition or RhoA activation rescues the hyper-activation of Gna13-deficient osteoclasts.","method":"Osteoclast-lineage-specific Gna13 conditional knockout mice, RNAi, Akt inhibitor and RhoA activator pharmacological rescue, signaling pathway analysis","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with pharmacological epistasis establishing pathway position of NFATc1","pmids":["28102206"],"is_preprint":false},{"year":2002,"finding":"GATA5 and NF-ATc (NFATc1) synergistically activate endocardial transcription; inhibition of either GATA5 expression or NF-ATc activation blocks terminal endocardial differentiation at a pre-endocardial stage, establishing cooperative regulation of endothelial-endocardial differentiation.","method":"In vitro cardiogenic differentiation model, inhibition of GATA5 and NF-ATc, reporter assay for endocardial gene expression","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 3 — loss-of-function in cell culture model with synergy reporter assay; single study","pmids":["12163407"],"is_preprint":false},{"year":2010,"finding":"Pim-1 kinase interacts with RANK and TAK1 and promotes RANKL-induced NF-κB activation via TAK1; overexpression of dominant-negative Pim-1 blocks RANKL-induced NFATc1 expression and osteoclastogenesis. Pim-1 also regulates NFATc1 transcriptional activity and OSCAR expression.","method":"Co-immunoprecipitation (Pim-1 with RANK and TAK1), dominant-negative overexpression, RNA interference, NF-κB and NFATc1 reporter assays","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP establishing Pim-1/RANK/TAK1 complex, with functional NFATc1 readout; moderate evidence","pmids":["21068407"],"is_preprint":false},{"year":2005,"finding":"CCR1 (chemokine receptor) acts as a downstream target of NFATc1/NFAT2 in RANKL-stimulated osteoclastogenesis; the CCR1 upstream regulatory region shows RANKL-dependent and cyclosporin A-suppressible promoter activity, and CCR1 silencing suppresses osteoclast precursor migration.","method":"Microarray analysis, quantitative RT-PCR, luciferase promoter reporter assay, cyclosporin A inhibition, CCR1 siRNA knockdown, Boyden chamber migration assay","journal":"Journal of Bone and Mineral Research","confidence":"Medium","confidence_rationale":"Tier 2 — promoter reporter with NFAT dependency plus functional migration assay; single study","pmids":["16355273"],"is_preprint":false},{"year":2023,"finding":"NFATc1 transcriptionally upregulates SLC7A11 expression during RANKL-induced osteoclastogenesis, driving cystine import and sensitivity to TXNRD1 inhibitor-induced disulfidptosis in osteoclast precursors.","method":"ChIP for NFATc1 binding at SLC7A11 locus, siRNA knockdown, SLC7A11 inhibitor rescue, in vivo OVX model","journal":"Redox Biology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP establishes direct NFATc1-SLC7A11 transcriptional regulation, with functional metabolic consequence","pmids":["37148740"],"is_preprint":false},{"year":2015,"finding":"PU.1 directly binds to the NFATc1 promoter in osteoclasts to transactivate NFATc1 expression; PU.1 knockdown reduces NFATc1 mRNA and promoter activity, while enforced PU.1 expression increases NFATc1 and osteoclast differentiation.","method":"ChIP for PU.1 binding at NFATc1 promoter, luciferase reporter assay, siRNA knockdown, retroviral enforced expression","journal":"Allergology International","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP demonstrates direct PU.1 binding at NFATc1 promoter with functional rescue; single study","pmids":["26117255"],"is_preprint":false},{"year":2020,"finding":"Nfatc1 promotes valve interstitial cell (VIC) formation in zebrafish atrioventricular valve by stimulating VIC proliferation and recruitement of endocardial and neural crest cells; nfatc1 mutants form fewer VICs. NFATc1 promotes expression of twist1b, a regulator of epithelial-to-mesenchymal transition, as a downstream effector.","method":"Zebrafish nfatc1 mutants, live imaging, high-speed microscopy and echocardiography, downstream effector analysis (twist1b expression)","journal":"Circulation Research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic mutant with downstream effector identification in zebrafish ortholog model","pmids":["32070236"],"is_preprint":false},{"year":2023,"finding":"The deubiquitinase UCHL1 deubiquitinates and stabilizes TAZ at K46 residue (preventing K48-linked polyubiquitination); stabilized TAZ then competes with calcineurin A for binding to NFATc1, inhibiting NFATc1 dephosphorylation and nuclear transport, thereby negatively regulating osteoclastogenesis.","method":"Co-IP (TAZ-NFATc1 and CNA-NFATc1 interaction), ubiquitination assay (K46 site), UCHL1 conditional knockout mice, proteomic analysis, OVX bone loss model","journal":"International Journal of Biological Sciences","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP demonstrating TAZ-NFATc1 competition with calcineurin, with ubiquitination site identified and in vivo validation","pmids":["37215988"],"is_preprint":false},{"year":2019,"finding":"Homer2 and Homer3 scaffold proteins regulate NFATc1 function by interacting with NFATc1 and modulating its interaction with calcineurin; RANKL treatment inhibits Homer protein interaction with NFATc1 (restored by cyclosporin A treatment). Homer2/3 double knockout increases NFATc1 expression and nuclear translocation without altering Ca2+ oscillations, demonstrating a Ca2+-independent regulation of NFATc1-calcineurin interaction.","method":"Homer2/3 double knockout mice, Co-IP of Homer proteins with NFATc1 and calcineurin, cyclosporin A treatment, Ca2+ oscillation measurement, NFATc1 nuclear translocation assay","journal":"Journal of Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP with genetic KO and cyclosporin A pharmacological rescue; moderate evidence","pmids":["31319381"],"is_preprint":false},{"year":2016,"finding":"The transcriptional coactivator/repressor Ifrd1 enhances NF-κB/NFATc1 signaling in osteoclasts; Ifrd1 deficiency increases p65 acetylation at K122/K123 via impaired histone deacetylase-dependent deacetylation, repressing NF-κB-dependent NFATc1 transcription and reducing osteoclastogenesis.","method":"Ifrd1 global and conditional knockout mice, histone acetylation analysis of p65, HDAC inhibitor studies, NFATc1 reporter and expression analysis","journal":"Molecular and Cellular Biology","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO with mechanistic analysis of p65 acetylation and NFATc1 transcription; moderate evidence","pmids":["27381458"],"is_preprint":false},{"year":2019,"finding":"RBP-J represses miR182 expression while NFATc1 activates miR182 transcription through binding to specific open chromatin regions in the miR182 promoter; RBP-J inhibition of miR182 limits TNF-induced osteoclast differentiation and inflammatory bone resorption.","method":"ChIP for NFATc1 and RBP-J binding at miR182 promoter, ATAC-seq for open chromatin, in vivo inflammatory arthritis model, TNF inhibitor treatment of RA patients","journal":"FASEB Journal","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP with open chromatin analysis demonstrating direct NFATc1 binding at miR182 promoter","pmids":["31908034"],"is_preprint":false},{"year":2011,"finding":"NFATc1 regulates TRAIL expression in intestinal cells through negative regulation of Sp1 binding to the TRAIL promoter; NFATc1 activation increases TRAIL expression by repressing Sp1 transcription factor binding to the TRAIL promoter.","method":"NFATc1 siRNA knockdown, NFATc1 overexpression, TRAIL promoter reporter assay with NFAT site deletion, ChIP for Sp1 binding, Sp1 chemical inhibition and siRNA","journal":"PLoS ONE","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP for Sp1 plus promoter deletion analysis establishing indirect NFATc1-Sp1-TRAIL regulatory mechanism","pmids":["21603612"],"is_preprint":false},{"year":2014,"finding":"NFATc1 activity regulates dexamethasone-induced myocilin (MYOC) expression in human trabecular meshwork cells; dexamethasone induces calcineurin-dependent NFATc1 nuclear translocation within 15 minutes in a calcium-independent mechanism, and NFATc1 siRNA knockdown reduces MYOC mRNA induction.","method":"NFATc1 siRNA knockdown, calcineurin inhibitors (cyclosporin A, INCA-6), immunofluorescence for NFATc1 nuclear translocation, ionomycin treatment control","journal":"Experimental Eye Research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pharmacological inhibitors and siRNA knockdown with localization assay; calcium-independent mechanism noted","pmids":["25450062"],"is_preprint":false},{"year":2009,"finding":"FOXP3 competes with NFAT1 for binding to the endogenous NFAT2 (NFATc1) promoter, suppressing NFATc1 transcription in regulatory T cells; ectopic NFAT2 expression partially restores IL-2 production in FOXP3+ Tregs, demonstrating that FOXP3-mediated repression of NFATc1 contributes to T cell anergy.","method":"ChIP for FOXP3 and NFAT1 at NFATc1 promoter, inducible FOXP3-expressing cell lines, retroviral NFAT2 overexpression, IL-2 reporter assay","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP competition assay at NFATc1 promoter with functional rescue; single study","pmids":["19564342"],"is_preprint":false},{"year":2022,"finding":"Cav2.2 (voltage-gated calcium channel) upregulates USP43 deubiquitinase expression through NFAT2 (NFATc1) dephosphorylation and nuclear localization, which then stabilizes cortactin to promote invadopodia formation and breast cancer metastasis.","method":"Co-immunoprecipitation, siRNA knockdown of Cav2.2/NFAT2/USP43, NFATc1 nuclear localization imaging, invasion assay, in vivo metastasis model","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway linking Cav2.2-NFATc1-USP43-cortactin with multiple knockdown validations; single study","pmids":["36137995"],"is_preprint":false},{"year":2022,"finding":"NFATc1 drives NAFLD progression through ER stress sensing and activation of the PERK-CHOP unfolded protein response (UPR) in hepatocytes; hepatocyte-specific NFATc1 depletion prevents disease acceleration in high-fat western diet-fed mice, and NFATc1 activation induces NLRP3 inflammasome activation.","method":"Hepatocyte-specific NFATc1 conditional knockout and overexpression transgenic mice, high-fat diet model, PERK-CHOP pathway analysis, NLRP3 inflammasome activation assay, TUDCA pharmacological inhibition","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 — dual conditional KO and overexpression mouse models with defined ER stress pathway mechanism","pmids":["35365570"],"is_preprint":false},{"year":2019,"finding":"CR3 engagement by M. leprae PGL-I activates the Syk tyrosine kinase, inducing calcineurin-dependent nuclear translocation of NFATc in innate immune cells (macrophages, neutrophils, dendritic cells), selectively augmenting production of IL-2 (DCs), IL-10 (PMNs), and IL-1β (macrophages).","method":"CR3 engagement assay, Syk kinase inhibitor, calcineurin inhibitor, NFATc nuclear translocation imaging, cytokine measurement in infected mice","journal":"Frontiers in Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological pathway dissection with multiple cell types and in vivo validation; single study","pmids":["31921172"],"is_preprint":false}],"current_model":"NFATc1 is a calcium/calcineurin-regulated transcription factor whose nuclear activity is controlled by a multi-kinase phosphorylation cycle: calcineurin dephosphorylates conserved serine residues (including SP-repeat motifs) to drive nuclear import, while GSK-3, JNK, ERK, p38, CK2, and DYRK1A phosphorylate these same or adjacent residues to promote nuclear export or protein stability; in osteoclasts, RANKL-induced Ca2+ oscillations activate calcineurin-NFATc1 signaling, and NFATc1 autoregulates its own P1 promoter to amplify expression, acting as a master transcriptional regulator of osteoclastogenesis by cooperating with PU.1, MITF, c-Fos, STAT3, and AP-1 at target gene promoters (cathepsin K, OSCAR, CCR1, SLC7A11); beyond bone, NFATc1 controls cardiac valve formation (endocardial cells, calcineurin-dependent nuclear entry), hair follicle stem cell quiescence (CDK4 repression downstream of BMP), PD-1 expression in T cells, TRAIL and myocilin expression, and is subject to SUMOylation (repressing IL-2) and epigenetic regulation via SSP-derived α-ketoglutarate-dependent histone demethylation at its gene locus."},"narrative":{"teleology":[{"year":1997,"claim":"Identifying the kinase that opposes calcineurin-mediated NFATc1 activation revealed that GSK-3 directly phosphorylates conserved N-terminal serines to drive nuclear export, establishing the core phosphorylation/dephosphorylation toggle governing NFATc1 subcellular localization.","evidence":"Biochemical purification of NFATc1 kinase activity followed by in vitro phosphorylation and nuclear localization assays","pmids":["9072970"],"confidence":"High","gaps":["Identity of the GSK-3 priming kinase was not resolved","In vivo significance of GSK-3-mediated export not tested"]},{"year":1998,"claim":"Genetic knockout and structural studies simultaneously revealed that NFATc1 is essential for cardiac valve formation—acting through calcineurin-dependent nuclear translocation in endocardial cells—and that its DNA-binding domain undergoes conformational reorientation upon cooperative complex formation with AP-1.","evidence":"NFATc1 knockout mice showing lethal valve defects with cyclosporin A phenocopy; NMR solution structure of NFATc1 DBD–DNA complex","pmids":["9515964","9506523"],"confidence":"High","gaps":["Downstream transcriptional targets in endocardial cells were not identified","Structural basis of full-length NFATc1 regulation by phosphorylation remained unknown"]},{"year":2000,"claim":"Expanding the kinase network controlling NFATc1 showed that JNK, ERK, p38, and CK2 each physically associate with and phosphorylate the N-terminal regulatory domain to block nuclear import, while GSK-3 phosphorylation was further shown to directly inhibit DNA-binding activity—not just localization.","evidence":"Co-immunoprecipitation and in vitro kinase assays with localization readouts; EMSA with GSK-3-phosphorylated NFATc1 and Ser-Pro repeat mutants","pmids":["10652349","11063740"],"confidence":"High","gaps":["Relative contributions of individual kinases in physiological contexts undetermined","Whether all kinases act simultaneously or in sequence was not addressed"]},{"year":2001,"claim":"Demonstrating pattern-specific nuclear translocation in adult muscle fibers established that NFATc1 decodes calcium signaling frequency, translocating only in response to slow-twitch stimulation patterns to control fiber-type gene expression.","evidence":"GFP-NFATc1 live imaging in electrically stimulated adult mouse skeletal muscle fibers with cyclosporin A validation","pmids":["11581284"],"confidence":"High","gaps":["Direct transcriptional targets in slow-twitch fibers not identified","Mechanism discriminating stimulation frequencies upstream of calcineurin unclear"]},{"year":2002,"claim":"The discovery that RANKL induces NFATc1 via TRAF6/c-Fos and Ca²⁺ oscillation–calcineurin signaling, and that NFATc1-deficient cells cannot form osteoclasts while ectopic NFATc1 suffices, established NFATc1 as the master transcription factor for osteoclastogenesis. Concurrently, autoregulation of the P1 promoter by the short NFATc1/αA isoform was identified in T cells.","evidence":"NFATc1−/− ES cell differentiation, retroviral ectopic expression bypassing RANKL, Ca²⁺ oscillation imaging; P1 promoter reporter dissection and isoform-specific expression analysis","pmids":["12479813","12121669"],"confidence":"High","gaps":["The full set of NFATc1 osteoclast target genes was not defined","Isoform-specific functions beyond apoptosis resistance remained unexplored"]},{"year":2003,"claim":"Establishing a cell-intrinsic requirement for NFATc1—but not NFATc2—in B-1a cell development demonstrated non-redundant roles of NFAT family members in lymphocyte lineage commitment.","evidence":"NFATc1−/− and NFATc2−/− mice, mixed-allotype chimeras, retroviral rescue, flow cytometry","pmids":["14595020"],"confidence":"High","gaps":["Downstream target genes in B-1a cells not identified","Mechanism of selective NFATc1 elevation in B-1a cells unknown"]},{"year":2005,"claim":"Demonstrating that NFATc1 autoregulates its own P1 promoter via tandem NFAT sites within a CpG island explained the sustained high expression unique to committed osteoclasts, and the inability of NFATc2 to substitute in vivo despite in vitro rescue capacity. Concurrently, CCR1 was identified as a direct NFATc1 target controlling osteoclast precursor migration.","evidence":"Adoptive transfer of NFATc1−/− HSCs, blastocyst complementation, ChIP/reporter for P1 autoregulation; CCR1 promoter reporter with cyclosporin A suppression and siRNA migration assay","pmids":["16275763","16355273"],"confidence":"High","gaps":["Epigenetic mechanism maintaining P1 CpG island accessibility not fully defined","Whether CCR1 regulation requires NFATc1 co-factors was not tested"]},{"year":2007,"claim":"ChIP at osteoclast target gene promoters revealed a sequential assembly model: MITF/PU.1 complexes pre-occupy promoters in response to CSF-1, RANKL adds p38-phosphorylated MITF and SWI/SNF, and NFATc1 is recruited last during terminal differentiation to sustain expression.","evidence":"ChIP at cathepsin K and ACP5 promoters, Co-IP of MITF/PU.1 complexes, MITF/PU.1 mouse models","pmids":["17403683"],"confidence":"High","gaps":["Order of factor departure from promoter upon signal withdrawal unknown","Whether SWI/SNF recruitment depends on NFATc1 not tested"]},{"year":2008,"claim":"Two non-overlapping roles were established: NFATc1 directly activates PD-1 transcription in T cells by binding a novel regulatory element at the pdcd1 locus, and NFATc1 maintains hair follicle stem cell quiescence by repressing CDK4 downstream of BMP signaling.","evidence":"ChIP and binding-site mutagenesis at the pdcd1 locus with reporter assay; conditional NFATc1 ablation in skin with CDK4 reporter analysis","pmids":["18802087","18243104"],"confidence":"High","gaps":["Co-factors mediating NFATc1 repression of CDK4 not identified","Whether NFATc1 regulates other immune checkpoint genes was not explored"]},{"year":2009,"claim":"FOXP3 was shown to compete with NFAT1 for binding at the NFATc1 promoter to suppress its transcription in Tregs, revealing a mechanism for Treg anergy; separately, VEGF and RANKL were found to activate NFATc1 through distinct co-signaling pathways (MEK/ERK vs. JNK) to control endocardial cushion cell proliferation versus cathepsin K induction during valve development.","evidence":"ChIP competition of FOXP3/NFAT1 at NFATc1 promoter, retroviral rescue of IL-2; NFATc1−/− mice plus chick ECC explants with pharmacological MEK/JNK/calcineurin inhibition","pmids":["19564342","19661463"],"confidence":"Medium","gaps":["Whether FOXP3-NFATc1 promoter competition occurs genome-wide is unknown","Quantitative contributions of MEK vs. JNK pathways in vivo not resolved"]},{"year":2011,"claim":"DYRK1A was identified as an NFATc1 kinase in osteoclasts (opposed by harmine inhibition), and NFATc1 was found to play a non-osteoclast role in epicardium-derived cells where RANKL/NFATc1 induces cathepsin K for extracellular matrix invasion during coronary vessel development.","evidence":"In vitro DYRK1A phosphorylation assay with harmine inhibition in RAW264.7 cells; conditional NFATc1 knockout in EPDCs with in vivo embryonic analysis","pmids":["21504804","21447555"],"confidence":"High","gaps":["Specific DYRK1A phosphorylation sites on NFATc1 were not mapped in this study","Other NFATc1 target genes in EPDCs beyond cathepsin K not explored"]},{"year":2014,"claim":"NFATc1 was shown to form a transcriptional complex with STAT3 that drives oncogenic enhancer-promoter communications in Kras-driven pancreatic carcinogenesis; separately, STAT3 was identified as a direct transcriptional activator of the NFATc1 promoter in osteoclasts, and NFATc1 was found to create a positive feedback loop by directly activating Itpr2 transcription in cardiomyocytes.","evidence":"Co-IP of NFATc1-STAT3, ChIP in pancreatic cancer GEMMs; conditional Stat3 KO with ChIP at NFATc1 promoter and rescue; ChIP at Itpr2 promoter in calcineurin-A transgenic mice","pmids":["24694735","31462535","24415751"],"confidence":"High","gaps":["Full genome-wide NFATc1-STAT3 co-occupancy map not generated","Whether Itpr2 feedback is specific to pathological hypertrophy or operates in normal physiology unclear"]},{"year":2015,"claim":"NFATc1 was found to cooperate with Sox2 to drive EMT and cancer stemness in pancreatic cancer, opposed by p53-miR200c, and PU.1 was shown to directly transactivate the NFATc1 promoter in osteoclasts.","evidence":"Co-IP of NFATc1-Sox2 in GEMM pancreatic cancer cells with EMT assays; ChIP for PU.1 at NFATc1 promoter with siRNA/retroviral rescue","pmids":["25586376","26117255"],"confidence":"High","gaps":["NFATc1-Sox2 direct versus indirect DNA co-binding not distinguished","Whether PU.1 transactivation of NFATc1 is independent of autoregulatory loop not tested"]},{"year":2017,"claim":"DYRK1A was shown to phosphorylate specific NFATc1/αA residues (S261, S278, S403, S409) that paradoxically stabilize the protein by blocking ubiquitin-proteasome degradation, contrasting its destabilizing effect on NFATc2; separately, Gα13-RhoA-Akt-GSK3β signaling was identified as a negative regulator of NFATc1 in osteoclasts.","evidence":"In vitro phosphorylation with site-specific mutants and ubiquitination assay; osteoclast-lineage Gna13 conditional KO with pharmacological epistasis","pmids":["28235034","28102206"],"confidence":"High","gaps":["Structural basis for divergent DYRK1A effects on NFATc1 vs. NFATc2 stability unknown","Whether Gα13 pathway operates in non-bone contexts not explored"]},{"year":2018,"claim":"Epigenetic regulation at the NFATc1 locus was established through ASXL1 loss, which reduces H3K27me3 and increases H3K4me3 at the NFATc1 promoter via Jmjd3 histone demethylase, explaining enhanced NFATc1 expression and osteoclastogenesis in ASXL1-deficient cells.","evidence":"Conditional ASXL1 KO in myeloid cells, ChIP for H3K27me3/H3K4me3 at NFATc1 promoter, Jmjd3 siRNA rescue","pmids":["30266822"],"confidence":"High","gaps":["Whether ASXL1-dependent epigenetic regulation of NFATc1 occurs outside the myeloid lineage unknown","Full set of Jmjd3-regulated loci beyond NFATc1 not defined"]},{"year":2019,"claim":"Homer2/3 scaffold proteins were identified as Ca²⁺-independent modulators that physically interact with NFATc1 and gate its access to calcineurin; RANKL disrupts the Homer–NFATc1 interaction to enable dephosphorylation and nuclear translocation.","evidence":"Homer2/3 double KO mice, Co-IP of Homer with NFATc1 and calcineurin, Ca²⁺ oscillation measurements showing no change, cyclosporin A rescue","pmids":["31319381"],"confidence":"Medium","gaps":["Structural basis of Homer–NFATc1 interaction not determined","Whether Homer regulation applies to non-osteoclast contexts unknown"]},{"year":2021,"claim":"SUMOylation of NFATc1 was shown to function as a post-translational switch that represses IL-2 production; preventing SUMOylation in knock-in mice elevated IL-2, expanded Tregs via STAT5/Blimp-1, and suppressed autoimmune and alloreactive responses.","evidence":"Transgenic knock-in mouse with prevented NFATc1 SUMO modification, EAE and GVHD disease models, cytokine and signaling analysis","pmids":["32986812"],"confidence":"High","gaps":["SUMO site(s) on NFATc1 and the E3 SUMO ligase were not identified in this study","Whether SUMOylation affects NFATc1 function outside T cells not addressed"]},{"year":2022,"claim":"NFATc1 was linked to hepatic ER stress: hepatocyte-specific depletion prevents NAFLD progression by blocking PERK-CHOP UPR and NLRP3 inflammasome activation, revealing a metabolic-inflammatory role beyond its canonical immune and bone functions.","evidence":"Hepatocyte-specific NFATc1 conditional KO and overexpression transgenic mice on high-fat diet, PERK-CHOP and NLRP3 pathway analysis","pmids":["35365570"],"confidence":"High","gaps":["Whether NFATc1 directly binds PERK or CHOP gene promoters not tested","Upstream signals activating NFATc1 in hepatocyte ER stress not defined"]},{"year":2024,"claim":"Metabolic control of NFATc1 expression was established: the serine synthesis pathway generates α-ketoglutarate that fuels histone demethylases removing H3K27me3 from the Nfatc1 locus, coupling amino acid metabolism to osteoclast maturation through epigenetic derepression.","evidence":"Conditional PHGDH KO in osteoclast progenitors, ChIP for H3K27me3 at Nfatc1 locus, α-ketoglutarate supplementation rescue","pmids":["38200114"],"confidence":"High","gaps":["Identity of the specific demethylase(s) acting at the Nfatc1 locus downstream of α-ketoglutarate not determined","Whether this metabolic-epigenetic axis regulates NFATc1 in non-osteoclast lineages unknown"]},{"year":null,"claim":"Despite extensive characterization of individual kinases, co-factors, and epigenetic inputs, the integrated quantitative logic by which NFATc1 integrates simultaneous phosphorylation by multiple kinases, SUMOylation, and epigenetic accessibility to produce tissue-specific transcriptional outputs remains undefined; no full-length structural model of NFATc1 in complex with calcineurin exists.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length NFATc1 structure or NFATc1–calcineurin co-structure available","Quantitative model of combinatorial post-translational modification integration lacking","Genome-wide map of NFATc1 occupancy across multiple cell types not generated in these studies"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3,4]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6,8,9,10,12,30]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,2,5,7,10,34]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,5,7]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,5,26]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,8,10,12,30]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,18,25,39]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,13,23,32]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[20,21]}],"complexes":["NFATc1-calcineurin","NFATc1-STAT3","NFATc1-Sox2","NFATc1-AP-1"],"partners":["GSK3B","STAT3","SOX2","SPI1","MITF","DYRK1A","HOMER2","HOMER3"],"other_free_text":[]},"mechanistic_narrative":"NFATc1 is a calcium/calcineurin-regulated transcription factor that integrates signal-dependent dephosphorylation with multi-kinase rephosphorylation to control gene expression across diverse developmental and homeostatic programs. Calcineurin dephosphorylates conserved serine residues to drive nuclear import and DNA binding, while GSK-3, JNK, ERK, p38, CK2, and DYRK1A phosphorylate overlapping or adjacent sites to promote nuclear export, inhibit DNA binding, or modulate protein stability [PMID:9072970, PMID:10652349, PMID:11063740, PMID:28235034]. NFATc1 functions as the master transcriptional switch for osteoclastogenesis—induced by RANKL/TRAF6/c-Fos signaling and sustained by autoregulation of its own P1 promoter—where it cooperates with PU.1, MITF, STAT3, and AP-1 to activate target genes including cathepsin K, OSCAR, CCR1, and SLC7A11 [PMID:12479813, PMID:16275763, PMID:17403683, PMID:31462535]. Beyond bone, NFATc1 is essential for cardiac valve morphogenesis through calcineurin-dependent nuclear entry in endocardial cells, maintains hair follicle stem cell quiescence by repressing CDK4, drives B-1a cell development, regulates PD-1 expression in T cells, and—when SUMOylated—represses IL-2 to shape regulatory T cell responses [PMID:9515964, PMID:18243104, PMID:14595020, PMID:18802087, PMID:32986812]."},"prefetch_data":{"uniprot":{"accession":"O95644","full_name":"Nuclear factor of activated T-cells, cytoplasmic 1","aliases":["NFAT transcription complex cytosolic component","NF-ATc","NFATc"],"length_aa":943,"mass_kda":101.2,"function":"Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2 or IL-4 gene transcription. Also controls gene expression in embryonic cardiac cells. Could regulate not only the activation and proliferation but also the differentiation and programmed death of T-lymphocytes as well as lymphoid and non-lymphoid cells (PubMed:10358178). Required for osteoclastogenesis and regulates many genes important for osteoclast differentiation and function (By similarity)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/O95644/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NFATC1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NFATC1","total_profiled":1310},"omim":[{"mim_id":"621356","title":"SH3 AND CYSTEINE-RICH DOMAINS 2; STAC2","url":"https://www.omim.org/entry/621356"},{"mim_id":"620638","title":"POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 4; KCTD4","url":"https://www.omim.org/entry/620638"},{"mim_id":"620432","title":"OSTEOCLAST STIMULATORY TRANSMEMBRANE PROTEIN; OCSTAMP","url":"https://www.omim.org/entry/620432"},{"mim_id":"618749","title":"LEUCINE-RICH REPEAT-CONTAINING PROTEIN 17; LRRC17","url":"https://www.omim.org/entry/618749"},{"mim_id":"617514","title":"IMMUNODEFICIENCY 52; IMD52","url":"https://www.omim.org/entry/617514"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear bodies","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"choroid plexus","ntpm":33.8}],"url":"https://www.proteinatlas.org/search/NFATC1"},"hgnc":{"alias_symbol":["NF-ATC","NFATc","NFAT2"],"prev_symbol":[]},"alphafold":{"accession":"O95644","domains":[{"cath_id":"2.60.40.340","chopping":"423-587","consensus_level":"high","plddt":91.9661,"start":423,"end":587},{"cath_id":"2.60.40.10","chopping":"598-695","consensus_level":"high","plddt":93.2293,"start":598,"end":695}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95644","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95644-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95644-F1-predicted_aligned_error_v6.png","plddt_mean":56.78},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NFATC1","jax_strain_url":"https://www.jax.org/strain/search?query=NFATC1"},"sequence":{"accession":"O95644","fasta_url":"https://rest.uniprot.org/uniprotkb/O95644.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95644/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95644"}},"corpus_meta":[{"pmid":"12479813","id":"PMC_12479813","title":"Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.","date":"2002","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/12479813","citation_count":2078,"is_preprint":false},{"pmid":"16275763","id":"PMC_16275763","title":"Autoamplification of NFATc1 expression determines its essential role in bone homeostasis.","date":"2005","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16275763","citation_count":714,"is_preprint":false},{"pmid":"9072970","id":"PMC_9072970","title":"Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9072970","citation_count":624,"is_preprint":false},{"pmid":"9515964","id":"PMC_9515964","title":"The transcription factor NF-ATc is essential for cardiac valve formation.","date":"1998","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9515964","citation_count":476,"is_preprint":false},{"pmid":"25489571","id":"PMC_25489571","title":"Regulation of NFATc1 in Osteoclast Differentiation.","date":"2014","source":"Journal of bone metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25489571","citation_count":437,"is_preprint":false},{"pmid":"18243104","id":"PMC_18243104","title":"NFATc1 balances quiescence and proliferation of skin stem cells.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18243104","citation_count":348,"is_preprint":false},{"pmid":"18802087","id":"PMC_18802087","title":"NFATc1 regulates PD-1 expression upon T cell activation.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18802087","citation_count":330,"is_preprint":false},{"pmid":"31367247","id":"PMC_31367247","title":"Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31367247","citation_count":174,"is_preprint":false},{"pmid":"12121669","id":"PMC_12121669","title":"Autoregulation of NFATc1/A expression facilitates effector T cells to escape from rapid apoptosis.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12121669","citation_count":166,"is_preprint":false},{"pmid":"7650004","id":"PMC_7650004","title":"NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7650004","citation_count":161,"is_preprint":false},{"pmid":"11581284","id":"PMC_11581284","title":"Activity-dependent nuclear translocation and intranuclear distribution of NFATc in adult skeletal muscle fibers.","date":"2001","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11581284","citation_count":145,"is_preprint":false},{"pmid":"17403683","id":"PMC_17403683","title":"MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17403683","citation_count":142,"is_preprint":false},{"pmid":"11063740","id":"PMC_11063740","title":"Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11063740","citation_count":129,"is_preprint":false},{"pmid":"10652349","id":"PMC_10652349","title":"Identification of amino acid residues and protein kinases involved in the regulation of NFATc subcellular localization.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10652349","citation_count":122,"is_preprint":false},{"pmid":"28102206","id":"PMC_28102206","title":"Gα13 negatively controls osteoclastogenesis through inhibition of the Akt-GSK3β-NFATc1 signalling pathway.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28102206","citation_count":119,"is_preprint":false},{"pmid":"12355451","id":"PMC_12355451","title":"NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12355451","citation_count":105,"is_preprint":false},{"pmid":"31431733","id":"PMC_31431733","title":"Artesunate attenuates LPS-induced osteoclastogenesis by suppressing TLR4/TRAF6 and PLCγ1-Ca2+-NFATc1 signaling pathway.","date":"2019","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/31431733","citation_count":105,"is_preprint":false},{"pmid":"24694735","id":"PMC_24694735","title":"Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D.","date":"2014","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/24694735","citation_count":104,"is_preprint":false},{"pmid":"9506523","id":"PMC_9506523","title":"Solution structure of the core NFATC1/DNA complex.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9506523","citation_count":97,"is_preprint":false},{"pmid":"31462535","id":"PMC_31462535","title":"STAT3 controls osteoclast differentiation and bone homeostasis by regulating NFATc1 transcription.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31462535","citation_count":92,"is_preprint":false},{"pmid":"25586376","id":"PMC_25586376","title":"Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity.","date":"2015","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/25586376","citation_count":85,"is_preprint":false},{"pmid":"22321691","id":"PMC_22321691","title":"Strontium ranelate rebalances bone marrow adipogenesis and osteoblastogenesis in senescent osteopenic mice through NFATc/Maf and Wnt signaling.","date":"2012","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/22321691","citation_count":82,"is_preprint":false},{"pmid":"32455661","id":"PMC_32455661","title":"The Role of Ca2+-NFATc1 Signaling and Its Modulation on Osteoclastogenesis.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32455661","citation_count":80,"is_preprint":false},{"pmid":"37148740","id":"PMC_37148740","title":"NFATc1-mediated expression of SLC7A11 drives sensitivity to TXNRD1 inhibitors in osteoclast precursors.","date":"2023","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/37148740","citation_count":79,"is_preprint":false},{"pmid":"12163407","id":"PMC_12163407","title":"Cooperative interaction between GATA5 and NF-ATc regulates endothelial-endocardial differentiation of cardiogenic cells.","date":"2002","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12163407","citation_count":78,"is_preprint":false},{"pmid":"23826864","id":"PMC_23826864","title":"NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.","date":"2013","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23826864","citation_count":73,"is_preprint":false},{"pmid":"16931157","id":"PMC_16931157","title":"NFATc1 autoregulation: a crucial step for cell-fate determination.","date":"2006","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16931157","citation_count":62,"is_preprint":false},{"pmid":"34801352","id":"PMC_34801352","title":"Dendrobine attenuates osteoclast differentiation through modulating ROS/NFATc1/ MMP9 pathway and prevents inflammatory bone destruction.","date":"2021","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34801352","citation_count":57,"is_preprint":false},{"pmid":"14595020","id":"PMC_14595020","title":"Normal B-1a cell development requires B cell-intrinsic NFATc1 activity.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14595020","citation_count":57,"is_preprint":false},{"pmid":"30816596","id":"PMC_30816596","title":"AP-1 and Mitf interact with NFATc1 to stimulate cathepsin K promoter activity in osteoclast precursors.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30816596","citation_count":56,"is_preprint":false},{"pmid":"19661463","id":"PMC_19661463","title":"VEGF and RANKL regulation of NFATc1 in heart valve development.","date":"2009","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/19661463","citation_count":56,"is_preprint":false},{"pmid":"35365570","id":"PMC_35365570","title":"NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression.","date":"2022","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/35365570","citation_count":54,"is_preprint":false},{"pmid":"30387123","id":"PMC_30387123","title":"Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca2+ -calcineurin-NFATc1 pathway.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30387123","citation_count":53,"is_preprint":false},{"pmid":"23665018","id":"PMC_23665018","title":"AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23665018","citation_count":50,"is_preprint":false},{"pmid":"16393972","id":"PMC_16393972","title":"Regulation of Th2 cytokine expression in NKT cells: unconventional use of Stat6, GATA-3, and NFAT2.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16393972","citation_count":50,"is_preprint":false},{"pmid":"27077737","id":"PMC_27077737","title":"Accelerated Lactate Dehydrogenase Activity Potentiates Osteoclastogenesis via NFATc1 Signaling.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27077737","citation_count":49,"is_preprint":false},{"pmid":"22722879","id":"PMC_22722879","title":"Calcineurin/NFATc1 pathway contributes to cell proliferation in hepatocellular carcinoma.","date":"2012","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22722879","citation_count":48,"is_preprint":false},{"pmid":"32070236","id":"PMC_32070236","title":"Nfatc1 Promotes Interstitial Cell Formation During Cardiac Valve Development in Zebrafish.","date":"2020","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/32070236","citation_count":47,"is_preprint":false},{"pmid":"21447555","id":"PMC_21447555","title":"NFATC1 promotes epicardium-derived cell invasion into myocardium.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21447555","citation_count":47,"is_preprint":false},{"pmid":"22484180","id":"PMC_22484180","title":"Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.","date":"2012","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/22484180","citation_count":46,"is_preprint":false},{"pmid":"32454224","id":"PMC_32454224","title":"Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32454224","citation_count":44,"is_preprint":false},{"pmid":"23340267","id":"PMC_23340267","title":"NFAT2 mediates high glucose-induced glomerular podocyte apoptosis through increased Bax expression.","date":"2013","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/23340267","citation_count":43,"is_preprint":false},{"pmid":"21504804","id":"PMC_21504804","title":"The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.","date":"2011","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/21504804","citation_count":38,"is_preprint":false},{"pmid":"38200114","id":"PMC_38200114","title":"The serine synthesis pathway drives osteoclast differentiation through epigenetic regulation of NFATc1 expression.","date":"2024","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38200114","citation_count":37,"is_preprint":false},{"pmid":"24415751","id":"PMC_24415751","title":"Calcineurin-NFATc regulates type 2 inositol 1,4,5-trisphosphate receptor (InsP3R2) expression during cardiac remodeling.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24415751","citation_count":37,"is_preprint":false},{"pmid":"26477312","id":"PMC_26477312","title":"NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26477312","citation_count":37,"is_preprint":false},{"pmid":"30827151","id":"PMC_30827151","title":"Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.","date":"2019","source":"The American journal of Chinese medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30827151","citation_count":37,"is_preprint":false},{"pmid":"21068407","id":"PMC_21068407","title":"Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21068407","citation_count":37,"is_preprint":false},{"pmid":"31183372","id":"PMC_31183372","title":"TRPV1 Induced Apoptosis of Colorectal Cancer Cells by Activating Calcineurin-NFAT2-p53 Signaling Pathway.","date":"2019","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/31183372","citation_count":36,"is_preprint":false},{"pmid":"23365084","id":"PMC_23365084","title":"NFATc1 induction in peripheral T and B lymphocytes.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23365084","citation_count":36,"is_preprint":false},{"pmid":"29056557","id":"PMC_29056557","title":"AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4.","date":"2017","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29056557","citation_count":35,"is_preprint":false},{"pmid":"19564342","id":"PMC_19564342","title":"FOXP3 inhibits activation-induced NFAT2 expression in T cells thereby limiting effector cytokine expression.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19564342","citation_count":35,"is_preprint":false},{"pmid":"30328352","id":"PMC_30328352","title":"TRPM3/TRPV4 regulates Ca2+-mediated RANKL/NFATc1 expression in osteoblasts.","date":"2018","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30328352","citation_count":34,"is_preprint":false},{"pmid":"36375645","id":"PMC_36375645","title":"Ginsenoside Rg1 attenuates glomerular fibrosis by inhibiting CD36/TRPC6/NFAT2 signaling in type 2 diabetes mellitus mice.","date":"2022","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36375645","citation_count":34,"is_preprint":false},{"pmid":"17785810","id":"PMC_17785810","title":"Reciprocal NFAT1 and NFAT2 nuclear localization in CD8+ anergic T cells is regulated by suboptimal calcium signaling.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17785810","citation_count":34,"is_preprint":false},{"pmid":"30419283","id":"PMC_30419283","title":"MicroRNA-499-5p regulates skeletal myofiber specification via NFATc1/MEF2C pathway and Thrap1/MEF2C axis.","date":"2018","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30419283","citation_count":33,"is_preprint":false},{"pmid":"27723141","id":"PMC_27723141","title":"Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Osteoclast Differentiation via the Ca2+ /NFATc1 Axis.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27723141","citation_count":33,"is_preprint":false},{"pmid":"16355273","id":"PMC_16355273","title":"CCR1 acts downstream of NFAT2 in osteoclastogenesis and enhances cell migration.","date":"2005","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/16355273","citation_count":32,"is_preprint":false},{"pmid":"30857415","id":"PMC_30857415","title":"Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis via NF-κB-NFATc1 signal pathway.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30857415","citation_count":32,"is_preprint":false},{"pmid":"34158848","id":"PMC_34158848","title":"Major vault protein (MVP) negatively regulates osteoclastogenesis via calcineurin-NFATc1 pathway inhibition.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/34158848","citation_count":30,"is_preprint":false},{"pmid":"25630465","id":"PMC_25630465","title":"NFAT1 deficit and NFAT2 deficit attenuate EAE via different mechanisms.","date":"2015","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25630465","citation_count":29,"is_preprint":false},{"pmid":"25152440","id":"PMC_25152440","title":"Mitf regulates osteoclastogenesis by modulating NFATc1 activity.","date":"2014","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25152440","citation_count":29,"is_preprint":false},{"pmid":"28921505","id":"PMC_28921505","title":"NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.","date":"2017","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28921505","citation_count":29,"is_preprint":false},{"pmid":"31991837","id":"PMC_31991837","title":"TGFβ1 Regulates Human RANKL-Induced Osteoclastogenesis via Suppression of NFATc1 Expression.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31991837","citation_count":28,"is_preprint":false},{"pmid":"29246953","id":"PMC_29246953","title":"Ca2+-Dependent Regulation of NFATc1 via KCa3.1 in Inflammatory Osteoclastogenesis.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29246953","citation_count":27,"is_preprint":false},{"pmid":"25054323","id":"PMC_25054323","title":"Arginine enhances osteoblastogenesis and inhibits adipogenesis through the regulation of Wnt and NFATc signaling in human mesenchymal stem cells.","date":"2014","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25054323","citation_count":27,"is_preprint":false},{"pmid":"32986812","id":"PMC_32986812","title":"Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32986812","citation_count":26,"is_preprint":false},{"pmid":"27381458","id":"PMC_27381458","title":"Transcriptional Modulator Ifrd1 Regulates Osteoclast Differentiation through Enhancing the NF-κB/NFATc1 Pathway.","date":"2016","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27381458","citation_count":26,"is_preprint":false},{"pmid":"30266822","id":"PMC_30266822","title":"ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/30266822","citation_count":26,"is_preprint":false},{"pmid":"15339657","id":"PMC_15339657","title":"Sculpting heart valves with NFATc and VEGF.","date":"2004","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15339657","citation_count":25,"is_preprint":false},{"pmid":"28235034","id":"PMC_28235034","title":"NFATc1 phosphorylation by DYRK1A increases its protein stability.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28235034","citation_count":25,"is_preprint":false},{"pmid":"37020186","id":"PMC_37020186","title":"RhoA promotes osteoclastogenesis and regulates bone remodeling through mTOR-NFATc1 signaling.","date":"2023","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/37020186","citation_count":25,"is_preprint":false},{"pmid":"32550905","id":"PMC_32550905","title":"Renal tubular Bim mediates the tubule-podocyte crosstalk via NFAT2 to induce podocyte cytoskeletal dysfunction.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32550905","citation_count":24,"is_preprint":false},{"pmid":"28245593","id":"PMC_28245593","title":"TNFα Increases RANKL Expression via PGE₂-Induced Activation of NFATc1.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28245593","citation_count":24,"is_preprint":false},{"pmid":"36137995","id":"PMC_36137995","title":"Cav2.2-NFAT2-USP43 axis promotes invadopodia formation and breast cancer metastasis through cortactin stabilization.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36137995","citation_count":23,"is_preprint":false},{"pmid":"25450062","id":"PMC_25450062","title":"NFATc1 activity regulates the expression of myocilin induced by dexamethasone.","date":"2014","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/25450062","citation_count":23,"is_preprint":false},{"pmid":"26117255","id":"PMC_26117255","title":"Involvement of PU.1 in NFATc1 promoter function in osteoclast development.","date":"2015","source":"Allergology international : official journal of the Japanese Society of Allergology","url":"https://pubmed.ncbi.nlm.nih.gov/26117255","citation_count":23,"is_preprint":false},{"pmid":"28161640","id":"PMC_28161640","title":"Gastrodin inhibits osteoclastogenesis via down-regulating the NFATc1 signaling pathway and stimulates osseointegration in vitro.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28161640","citation_count":23,"is_preprint":false},{"pmid":"31868826","id":"PMC_31868826","title":"Role of NFATc1 in the Bone-Vascular Axis Calcification Paradox.","date":"2020","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31868826","citation_count":22,"is_preprint":false},{"pmid":"31127093","id":"PMC_31127093","title":"MiR-30 family prevents uPAR-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31127093","citation_count":22,"is_preprint":false},{"pmid":"29609502","id":"PMC_29609502","title":"Fluid shear stress promotes osteoblast proliferation through the NFATc1-ERK5 pathway.","date":"2018","source":"Connective tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/29609502","citation_count":22,"is_preprint":false},{"pmid":"26106221","id":"PMC_26106221","title":"Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxIxIT motif of calcineurin binding partners.","date":"2015","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/26106221","citation_count":22,"is_preprint":false},{"pmid":"30828328","id":"PMC_30828328","title":"NFAT1 and NFAT2 Differentially Regulate CTL Differentiation Upon Acute Viral Infection.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30828328","citation_count":21,"is_preprint":false},{"pmid":"32372426","id":"PMC_32372426","title":"miR-506-3p alleviates uncontrolled osteoclastogenesis via repression of RANKL/NFATc1 signaling pathway.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32372426","citation_count":21,"is_preprint":false},{"pmid":"21678407","id":"PMC_21678407","title":"Lithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (nuclear factor of activated T cells 2).","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21678407","citation_count":21,"is_preprint":false},{"pmid":"34858489","id":"PMC_34858489","title":"HIF-Dependent NFATC1 Activation Upregulates ITGA5 and PLAUR in Intestinal Epithelium in Inflammatory Bowel Disease.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34858489","citation_count":21,"is_preprint":false},{"pmid":"22615493","id":"PMC_22615493","title":"Cot kinase promotes Ca2+ oscillation/calcineurin-independent osteoclastogenesis by stabilizing NFATc1 protein.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22615493","citation_count":19,"is_preprint":false},{"pmid":"35955685","id":"PMC_35955685","title":"Osteostatin Inhibits M-CSF+RANKL-Induced Human Osteoclast Differentiation by Modulating NFATc1.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35955685","citation_count":19,"is_preprint":false},{"pmid":"31908034","id":"PMC_31908034","title":"Regulatory network mediated by RBP-J/NFATc1-miR182 controls inflammatory bone resorption.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31908034","citation_count":18,"is_preprint":false},{"pmid":"31921172","id":"PMC_31921172","title":"CR3 Engaged by PGL-I Triggers Syk-Calcineurin-NFATc to Rewire the Innate Immune Response in Leprosy.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31921172","citation_count":18,"is_preprint":false},{"pmid":"21603612","id":"PMC_21603612","title":"NFATc1 regulation of TRAIL expression in human intestinal cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21603612","citation_count":18,"is_preprint":false},{"pmid":"31964469","id":"PMC_31964469","title":"Dehydrocostus lactone inhibits NFATc1 via regulation of IKK, JNK, and Nrf2, thereby attenuating osteoclastogenesis.","date":"2020","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/31964469","citation_count":18,"is_preprint":false},{"pmid":"31319381","id":"PMC_31319381","title":"Homer2 and Homer3 modulate RANKL-induced NFATc1 signaling in osteoclastogenesis and bone metabolism.","date":"2019","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31319381","citation_count":17,"is_preprint":false},{"pmid":"21384111","id":"PMC_21384111","title":"Retinoic acid inhibits NFATc1 expression and osteoclast differentiation.","date":"2011","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21384111","citation_count":17,"is_preprint":false},{"pmid":"29907883","id":"PMC_29907883","title":"B cell development is critically dependent on NFATc1 activity.","date":"2018","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29907883","citation_count":17,"is_preprint":false},{"pmid":"37215988","id":"PMC_37215988","title":"The deubiquitinase UCHL1 negatively controls osteoclastogenesis by regulating TAZ/NFATC1 signalling.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37215988","citation_count":17,"is_preprint":false},{"pmid":"38614385","id":"PMC_38614385","title":"FPR3 reprograms glycolytic metabolism and stemness in gastric cancer via calcium-NFATc1 pathway.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38614385","citation_count":16,"is_preprint":false},{"pmid":"31362013","id":"PMC_31362013","title":"High expression of NFAT2 contributes to carboplatin resistance in lung cancer.","date":"2019","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31362013","citation_count":16,"is_preprint":false},{"pmid":"25179582","id":"PMC_25179582","title":"NF-κB factors control the induction of NFATc1 in B lymphocytes.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25179582","citation_count":16,"is_preprint":false},{"pmid":"10906142","id":"PMC_10906142","title":"Grb3-3 is up-regulated in HIV-1-infected T-cells and can potentiate cell activation through NFATc.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10906142","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50948,"output_tokens":10744,"usd":0.157002},"stage2":{"model":"claude-opus-4-6","input_tokens":14707,"output_tokens":5377,"usd":0.31194},"total_usd":0.468942,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"RANKL selectively induces NFATc1 expression via TRAF6 and c-Fos signaling pathways, and RANKL-evoked Ca2+ oscillations lead to calcineurin-mediated activation (dephosphorylation) of NFATc1, triggering a sustained NFATc1-dependent transcriptional program during osteoclast differentiation. NFATc1-deficient embryonic stem cells fail to differentiate into osteoclasts, and ectopic NFATc1 expression drives osteoclastogenesis without RANKL, establishing NFATc1 as the master transcriptional switch downstream of RANKL.\",\n      \"method\": \"Genetic knockout (NFATc1-/- ES cells), retroviral ectopic expression, Ca2+ oscillation imaging, calcineurin inhibitor studies\",\n      \"journal\": \"Developmental Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (KO, overexpression, signaling pathway analysis), replicated across subsequent studies\",\n      \"pmids\": [\"12479813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Glycogen synthase kinase-3 (GSK-3) phosphorylates conserved serine residues in the N-terminus of NFATc1, promoting nuclear export and opposing Ca2+-calcineurin-mediated nuclear import. GSK-3 was purified as the NFATc1 kinase (together with a priming kinase activity) and shown to directly phosphorylate NFATc1 conserved serines required for nuclear export.\",\n      \"method\": \"Biochemical purification of NFATc1 kinase activity, in vitro phosphorylation assay, nuclear localization studies\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase reconstitution with biochemical purification; foundational paper with >600 citations\",\n      \"pmids\": [\"9072970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"NFATc1 is essential for cardiac valve formation (aortic and pulmonary valves); it is expressed specifically in cardiac endothelial cells and its nuclear translocation in endocardial cells is controlled by calcineurin, as demonstrated by cyclosporin A treatment retaining NFATc1 in the cytoplasm of normal embryos.\",\n      \"method\": \"Targeted gene disruption (knockout mice), calcineurin inhibitor (cyclosporin A) treatment, immunolocalization in cardiac endothelial cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined cardiac phenotype plus pharmacological calcineurin inhibition; >470 citations\",\n      \"pmids\": [\"9515964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Solution NMR structure of the binary NFATC1 DNA-binding domain (DBD) complexed with the ARRE2 DNA site from the IL-2 promoter reveals that DNA binding induces folding of structural elements required for sequence-specific recognition and cooperative protein-protein contacts; the orientation of NFAT DBD in the binary complex differs from that in the ternary NFATC2/AP-1/DNA complex, indicating domain reorientation upon formation of a cooperative transcriptional complex.\",\n      \"method\": \"NMR solution structure determination\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure of the core DBD-DNA complex with functional interpretation\",\n      \"pmids\": [\"9506523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"GSK-3 inhibits the intrinsic DNA-binding activity of NFATc1 by phosphorylating the conserved Ser-Pro repeat motifs; calcineurin dephosphorylation enhances DNA binding, while in vitro phosphorylation of NFATc1 by GSK-3 inhibits its ability to bind DNA, demonstrating regulation at the level of DNA-binding activity in addition to subcellular localization.\",\n      \"method\": \"Gel mobility shift assay (EMSA), in vitro phosphorylation, calcineurin activation in cells, NFATc1 Ser-Pro repeat mutant analysis\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical assays with mutant analysis and cell-based validation\",\n      \"pmids\": [\"11063740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"JNK, ERK, p38, and CK2 physically associate with the NFATc1 N-terminal regulatory domain, directly phosphorylate Ser172 and the conserved Ser-Pro repeats to regulate nuclear localization, and overexpression of JNK, ERK, or p38 blocks ionomycin-induced NFATc1 nuclear translocation. CK2 also binds the N-terminus and phosphorylates a conserved motif downstream of Ser-Pro repeats important for nuclear export.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assays, subcellular localization studies, overexpression and pharmacological inhibition of kinases\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding and direct phosphorylation with functional localization readout, multiple kinases tested\",\n      \"pmids\": [\"10652349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NFATc1 autoregulates its own expression through its P1 promoter (within a CpG island): NFATc1 binds tandemly arranged NFAT sites in its own promoter to sustain high-level expression selectively in osteoclasts in vivo. This autoregulatory loop explains why NFATc2 can rescue osteoclastogenesis in vitro but not in vivo, since NFATc1 autoregulation at the epigenetic level is uniquely required for cell-lineage commitment.\",\n      \"method\": \"Adoptive transfer of NFATc1-/- hematopoietic stem cells, blastocyst complementation, retroviral rescue, promoter analysis (ChIP, reporter assays), NFATc1 ectopic expression\",\n      \"journal\": \"Journal of Experimental Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic rescue combined with promoter/epigenetic mechanistic studies; >700 citations\",\n      \"pmids\": [\"16275763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NFATc1 undergoes activity-dependent, calcineurin-sensitive nuclear translocation in adult skeletal muscle fibers specifically in response to slow-twitch (10 Hz continuous or 10 Hz trains) but not fast-twitch stimulation patterns, contributing to slow-twitch fiber type-specific gene expression. Constitutively active NFATc1(S→A) shows a distinct intranuclear foci pattern in unstimulated fibers.\",\n      \"method\": \"GFP-fusion protein live imaging in cultured adult mouse skeletal muscle fibers, electrical stimulation with defined patterns, cyclosporin A (calcineurin inhibitor) treatment\",\n      \"journal\": \"Journal of Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live cell imaging with functional stimulation parameters and pharmacological validation\",\n      \"pmids\": [\"11581284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The short isoform NFATc1/αA is selectively induced to high levels via autoregulation of the NFATc1 P1 promoter (containing tandem NFAT binding sites within a CpG island DNase I hypersensitive site) by NFATs in effector T cells. This isoform does not promote apoptosis (unlike other NFATs), enhancing effector T cell survival. A second promoter P2 before exon 2 is not NFAT-controlled and directs longer isoforms.\",\n      \"method\": \"Promoter reporter assay, DNase I hypersensitivity mapping, NFAT binding site mutation, apoptosis assays, isoform-specific expression analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter dissection with multiple methods and functional isoform characterization\",\n      \"pmids\": [\"12121669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NFATc1 is preferentially expressed in hair follicle stem cells in their niche where it acts downstream of BMP signaling to transcriptionally repress CDK4 and maintain stem cell quiescence. Pharmacological or genetic NFATc1 ablation leads to premature stem cell activation and precocious follicular growth.\",\n      \"method\": \"Conditional and complete NFATc1 gene ablation, cyclosporin A pharmacological suppression, CDK4 reporter assays, hair follicle stem cell analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined molecular target (CDK4 repression) and phenotypic readout; >340 citations\",\n      \"pmids\": [\"18243104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NFATc1 directly binds to a novel regulatory element at the pdcd1 (PD-1) locus to regulate PD-1 gene expression upon T cell activation; NFATc1 binding was demonstrated by ChIP assay, and mutation of the NFATc1 binding site completely abolished promoter activity.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assay with NFATc1 binding site mutation, calcineurin inhibitor (cyclosporin A) and NFAT inhibitor treatment\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus mutagenesis of binding site with functional reporter readout\",\n      \"pmids\": [\"18802087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"During osteoclast differentiation, MITF and PU.1 form complexes at osteoclast target gene promoters (cathepsin K, acid phosphatase 5) in response to CSF-1 alone, while RANKL+CSF-1 additionally recruit p38 MAPK-phosphorylated MITF and SWI/SNF chromatin-remodeling complexes. NFATc1 is subsequently recruited to these promoter complexes during terminal differentiation to maintain target gene expression.\",\n      \"method\": \"ChIP on target gene promoters, Co-IP of transcription factor complexes, MITF/PU.1 mouse genetic models\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and Co-IP with genetic validation in mouse models\",\n      \"pmids\": [\"17403683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NFATc1 forms a transcriptional complex with STAT3 in pancreatic epithelial cells that promotes KrasG12D-driven carcinogenesis; NFATc1-STAT3 complexes mediate enhancer-promoter communications at jointly regulated oncogenic genes (Cyclin, EGFR, WNT family members). Genetic or pharmacologic NFATc1 ablation attenuates inflammation-induced carcinogenesis.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, genetic mouse models (NFATc1 activation/ablation in KrasG12D background), pharmacological inhibition\",\n      \"journal\": \"Cancer Discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP of NFATc1-STAT3 complex, ChIP for enhancer-promoter contacts, in vivo mouse genetic models\",\n      \"pmids\": [\"24694735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RANKL/NFATc1 signaling in epicardium-derived cells (EPDCs) induces cathepsin K (CTSK) expression for extracellular matrix degradation and cell invasion into myocardium; conditional loss of NFATc1 in EPDCs reduces coronary vessel and fibrous matrix penetration. RANKL treatment induces Ctsk expression in PE-derived cell cultures via a calcineurin-dependent mechanism.\",\n      \"method\": \"Conditional knockout of NFATc1 in EPDCs, calcineurin inhibitor treatment, RANKL stimulation of PE-derived cell cultures, in vivo embryonic analysis\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with specific molecular target (CTSK) and in vivo phenotypic consequence\",\n      \"pmids\": [\"21447555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"STAT3 drives the transcription of NFATc1 by directly binding to its promoter in osteoclasts; STAT3-deficient bone marrow macrophages show decreased NFATc1 expression and impaired osteoclast differentiation, which is rescued by enforced NFATc1 expression.\",\n      \"method\": \"Conditional Stat3 knockout (Ctsk-Cre), ChIP for STAT3 binding to NFATc1 promoter, siRNA knockdown of STAT3, enforced NFATc1 expression rescue\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO, ChIP, and rescue experiment with multiple orthogonal approaches\",\n      \"pmids\": [\"31462535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DYRK1A phosphorylates NFATc1/αA at S261, S278, S403, and S409, interfering with NFATc1 ubiquitination and ubiquitin-proteasome degradation, thereby increasing NFATc1 protein stability and transcriptional activity (in contrast to its known role in destabilizing NFATc2).\",\n      \"method\": \"In vitro phosphorylation assay with site-specific mutants, ubiquitination assay, protein stability analysis\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro phosphorylation with site-specific mutagenesis and ubiquitination functional readout\",\n      \"pmids\": [\"28235034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DYRK1A directly inhibits NFATc1 through phosphorylation (inactivation); harmine, a DYRK1A inhibitor, promotes NFATc1 dephosphorylation/activation in osteoclast precursors. In vitro phosphorylation assay demonstrated that harmine directly inhibited DYRK1A-mediated phosphorylation of NFATc1.\",\n      \"method\": \"In vitro phosphorylation assay, harmine treatment of RAW264.7 and bone marrow macrophages, NFATc1 expression analysis\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay, but single study with limited mutagenesis\",\n      \"pmids\": [\"21504804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Cot kinase (Tpl-2) directly phosphorylates all Ca2+/calcineurin-regulated NFAT family members (NFATc1–NFATc4) and increases their protein stability/levels, promoting Ca2+ oscillation/calcineurin-independent osteoclastogenesis. Cot activity was enhanced by osteoblast–osteoclast cell-cell interaction.\",\n      \"method\": \"In vitro kinase assay, co-culture system, Cot overexpression/knockdown in osteoclasts, protein stability analysis\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro phosphorylation of NFATc1 by Cot with functional validation in cell-cell interaction model\",\n      \"pmids\": [\"22615493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SUMOylation of NFATc1 represses IL-2 production in T cells; mice with prevented NFATc1 SUMOylation show elevated IL-2, expanded Tregs, and suppressed autoreactive/alloreactive immune responses. Increased IL-2 from non-SUMOylated NFATc1 counteracts IL-17 and IFN-γ through STAT5 and Blimp-1 induction.\",\n      \"method\": \"Transgenic knock-in mouse (SUMO modification prevented), EAE and graft-versus-host disease models, cytokine profiling, signaling analysis\",\n      \"journal\": \"Journal of Experimental Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — novel transgenic mouse with defined SUMO-site mutation and in vivo immune phenotype with mechanistic pathway analysis\",\n      \"pmids\": [\"32986812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NFATc1 forms a complex with Sox2 to drive EMT reprogramming and maintain pancreatic cancer cells in a stem cell-like state; NFATc1-Sox2-mediated dedifferentiation is opposed by antithetical p53-miR200c signaling.\",\n      \"method\": \"Co-immunoprecipitation of NFATc1-Sox2 complex, genetic mouse models (GEMM), NFATc1 knockdown/overexpression, in vitro EMT assays\",\n      \"journal\": \"EMBO Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP of NFATc1-Sox2 complex with GEMM validation and functional EMT assays\",\n      \"pmids\": [\"25586376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The serine synthesis pathway (SSP)-derived α-ketoglutarate is necessary for histone demethylases that remove repressive H3K27me3 marks at the Nfatc1 gene locus, inducing NFATc1 expression and consequent osteoclast maturation. Deletion of the rate-limiting SSP enzyme phosphoglycerate dehydrogenase impairs osteoclast differentiation and increases bone mass.\",\n      \"method\": \"Conditional knockout of PHGDH in osteoclast progenitors, histone methylation ChIP at Nfatc1 locus, pharmacological PHGDH inhibition, α-ketoglutarate metabolite supplementation\",\n      \"journal\": \"Nature Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO, ChIP for histone marks at Nfatc1 locus, metabolic-epigenetic mechanistic link established\",\n      \"pmids\": [\"38200114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ASXL1 loss induces concordant reduction of inhibitory H3K27me3 and gain of H3K4me3 at the NFATc1 and itgb3 gene loci, leading to increased NFATc1 expression and enhanced osteoclastogenesis. Jmjd3 histone demethylase knockdown in ASXL1-deficient precursors restores H3K27me3 on the NFATc1 promoter and impairs osteoclast formation.\",\n      \"method\": \"Conditional ASXL1 knockout in myeloid cells, ChIP for H3K27me3/H3K4me3 at NFATc1 promoter, Jmjd3 siRNA knockdown\",\n      \"journal\": \"Blood Advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP for histone modifications at NFATc1 locus, genetic rescue experiment with Jmjd3 knockdown\",\n      \"pmids\": [\"30266822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NFATc1 regulates the expression of InsP3R2 (type 2 inositol 1,4,5-trisphosphate receptor) by directly binding to the Itpr2 promoter; calcineurin-NFATc signaling drives Itpr2 transcription in cardiomyocytes, creating a positive feedback loop between InsP3R2 and calcineurin-NFATc signaling during cardiac hypertrophy.\",\n      \"method\": \"ChIP for NFATc1 binding at Itpr2 promoter, promoter-reporter assay, cyclosporin A inhibition, calcineurin-A transgenic mice, hypertrophic agonist stimulation\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct ChIP of NFATc1 at Itpr2 promoter, in vivo calcineurin transgenic validation\",\n      \"pmids\": [\"24415751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"VEGF activates NFATc1 via calcineurin and MEK1-ERK1/2-dependent signaling to promote endocardial cushion cell proliferation during valve development; subsequently RANKL inhibits VEGF-induced proliferation while inducing cathepsin K via calcineurin/NFATc1 and JNK1/2-dependent signaling, demonstrating ligand-specific cofactor cooperation.\",\n      \"method\": \"NFATc1-/- mice analysis, chick ECC explant cultures, pharmacological inhibition of calcineurin/MEK/JNK, VEGF/RANKL stimulation\",\n      \"journal\": \"Circulation Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout combined with pharmacological pathway dissection in ex vivo explant model\",\n      \"pmids\": [\"19661463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The cytoplasmic ITIM motif of DC-STAMP regulates NFATc1 nuclear translocation and expression; deletion of ITIM elevates Ca2+ flux amplitude/duration and alters NFATc1-dependent osteoclast phenotypes. DC-STAMP overexpression restores NFATc1 expression in DC-STAMP-/- cells.\",\n      \"method\": \"Light-activatable DC-STAMP chimeric molecule, Ca2+ flux imaging, ITIM deletion mutants, NFATc1 nuclear translocation assay, DC-STAMP overexpression\",\n      \"journal\": \"Journal of Cellular Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — engineered chimeric molecule for signaling studies, but mechanistic link between ITIM and NFATc1 is partly correlative\",\n      \"pmids\": [\"27723141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NFATc1 is required cell-intrinsically for normal B-1a cell development; NFATc1 protein is elevated ~5-fold in B-1a cells compared with B-2 cells, and the B-1a compartment is essentially absent in NFATc1-/- mice but normal in NFATc2-/- mice. Mixed-allotype chimeras and retroviral gene transduction confirmed the B cell-intrinsic requirement.\",\n      \"method\": \"NFATc1-/- and NFATc2-/- mouse analysis, mixed-allotype chimeras, retroviral NFATc1 gene transduction, flow cytometry\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO combined with chimera and retroviral rescue experiments definitively establishing cell-intrinsic function\",\n      \"pmids\": [\"14595020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Gα13 negatively regulates osteoclastogenesis through the RhoA/Akt/GSK3β/NFATc1 signaling pathway; Gna13-deficiency decreases RhoA activity and enhances Akt/GSK3β/NFATc1 signaling. Akt inhibition or RhoA activation rescues the hyper-activation of Gna13-deficient osteoclasts.\",\n      \"method\": \"Osteoclast-lineage-specific Gna13 conditional knockout mice, RNAi, Akt inhibitor and RhoA activator pharmacological rescue, signaling pathway analysis\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with pharmacological epistasis establishing pathway position of NFATc1\",\n      \"pmids\": [\"28102206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"GATA5 and NF-ATc (NFATc1) synergistically activate endocardial transcription; inhibition of either GATA5 expression or NF-ATc activation blocks terminal endocardial differentiation at a pre-endocardial stage, establishing cooperative regulation of endothelial-endocardial differentiation.\",\n      \"method\": \"In vitro cardiogenic differentiation model, inhibition of GATA5 and NF-ATc, reporter assay for endocardial gene expression\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — loss-of-function in cell culture model with synergy reporter assay; single study\",\n      \"pmids\": [\"12163407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Pim-1 kinase interacts with RANK and TAK1 and promotes RANKL-induced NF-κB activation via TAK1; overexpression of dominant-negative Pim-1 blocks RANKL-induced NFATc1 expression and osteoclastogenesis. Pim-1 also regulates NFATc1 transcriptional activity and OSCAR expression.\",\n      \"method\": \"Co-immunoprecipitation (Pim-1 with RANK and TAK1), dominant-negative overexpression, RNA interference, NF-κB and NFATc1 reporter assays\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP establishing Pim-1/RANK/TAK1 complex, with functional NFATc1 readout; moderate evidence\",\n      \"pmids\": [\"21068407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCR1 (chemokine receptor) acts as a downstream target of NFATc1/NFAT2 in RANKL-stimulated osteoclastogenesis; the CCR1 upstream regulatory region shows RANKL-dependent and cyclosporin A-suppressible promoter activity, and CCR1 silencing suppresses osteoclast precursor migration.\",\n      \"method\": \"Microarray analysis, quantitative RT-PCR, luciferase promoter reporter assay, cyclosporin A inhibition, CCR1 siRNA knockdown, Boyden chamber migration assay\",\n      \"journal\": \"Journal of Bone and Mineral Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter reporter with NFAT dependency plus functional migration assay; single study\",\n      \"pmids\": [\"16355273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NFATc1 transcriptionally upregulates SLC7A11 expression during RANKL-induced osteoclastogenesis, driving cystine import and sensitivity to TXNRD1 inhibitor-induced disulfidptosis in osteoclast precursors.\",\n      \"method\": \"ChIP for NFATc1 binding at SLC7A11 locus, siRNA knockdown, SLC7A11 inhibitor rescue, in vivo OVX model\",\n      \"journal\": \"Redox Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP establishes direct NFATc1-SLC7A11 transcriptional regulation, with functional metabolic consequence\",\n      \"pmids\": [\"37148740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PU.1 directly binds to the NFATc1 promoter in osteoclasts to transactivate NFATc1 expression; PU.1 knockdown reduces NFATc1 mRNA and promoter activity, while enforced PU.1 expression increases NFATc1 and osteoclast differentiation.\",\n      \"method\": \"ChIP for PU.1 binding at NFATc1 promoter, luciferase reporter assay, siRNA knockdown, retroviral enforced expression\",\n      \"journal\": \"Allergology International\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrates direct PU.1 binding at NFATc1 promoter with functional rescue; single study\",\n      \"pmids\": [\"26117255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Nfatc1 promotes valve interstitial cell (VIC) formation in zebrafish atrioventricular valve by stimulating VIC proliferation and recruitement of endocardial and neural crest cells; nfatc1 mutants form fewer VICs. NFATc1 promotes expression of twist1b, a regulator of epithelial-to-mesenchymal transition, as a downstream effector.\",\n      \"method\": \"Zebrafish nfatc1 mutants, live imaging, high-speed microscopy and echocardiography, downstream effector analysis (twist1b expression)\",\n      \"journal\": \"Circulation Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic mutant with downstream effector identification in zebrafish ortholog model\",\n      \"pmids\": [\"32070236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The deubiquitinase UCHL1 deubiquitinates and stabilizes TAZ at K46 residue (preventing K48-linked polyubiquitination); stabilized TAZ then competes with calcineurin A for binding to NFATc1, inhibiting NFATc1 dephosphorylation and nuclear transport, thereby negatively regulating osteoclastogenesis.\",\n      \"method\": \"Co-IP (TAZ-NFATc1 and CNA-NFATc1 interaction), ubiquitination assay (K46 site), UCHL1 conditional knockout mice, proteomic analysis, OVX bone loss model\",\n      \"journal\": \"International Journal of Biological Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP demonstrating TAZ-NFATc1 competition with calcineurin, with ubiquitination site identified and in vivo validation\",\n      \"pmids\": [\"37215988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Homer2 and Homer3 scaffold proteins regulate NFATc1 function by interacting with NFATc1 and modulating its interaction with calcineurin; RANKL treatment inhibits Homer protein interaction with NFATc1 (restored by cyclosporin A treatment). Homer2/3 double knockout increases NFATc1 expression and nuclear translocation without altering Ca2+ oscillations, demonstrating a Ca2+-independent regulation of NFATc1-calcineurin interaction.\",\n      \"method\": \"Homer2/3 double knockout mice, Co-IP of Homer proteins with NFATc1 and calcineurin, cyclosporin A treatment, Ca2+ oscillation measurement, NFATc1 nuclear translocation assay\",\n      \"journal\": \"Journal of Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with genetic KO and cyclosporin A pharmacological rescue; moderate evidence\",\n      \"pmids\": [\"31319381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The transcriptional coactivator/repressor Ifrd1 enhances NF-κB/NFATc1 signaling in osteoclasts; Ifrd1 deficiency increases p65 acetylation at K122/K123 via impaired histone deacetylase-dependent deacetylation, repressing NF-κB-dependent NFATc1 transcription and reducing osteoclastogenesis.\",\n      \"method\": \"Ifrd1 global and conditional knockout mice, histone acetylation analysis of p65, HDAC inhibitor studies, NFATc1 reporter and expression analysis\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with mechanistic analysis of p65 acetylation and NFATc1 transcription; moderate evidence\",\n      \"pmids\": [\"27381458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RBP-J represses miR182 expression while NFATc1 activates miR182 transcription through binding to specific open chromatin regions in the miR182 promoter; RBP-J inhibition of miR182 limits TNF-induced osteoclast differentiation and inflammatory bone resorption.\",\n      \"method\": \"ChIP for NFATc1 and RBP-J binding at miR182 promoter, ATAC-seq for open chromatin, in vivo inflammatory arthritis model, TNF inhibitor treatment of RA patients\",\n      \"journal\": \"FASEB Journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with open chromatin analysis demonstrating direct NFATc1 binding at miR182 promoter\",\n      \"pmids\": [\"31908034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NFATc1 regulates TRAIL expression in intestinal cells through negative regulation of Sp1 binding to the TRAIL promoter; NFATc1 activation increases TRAIL expression by repressing Sp1 transcription factor binding to the TRAIL promoter.\",\n      \"method\": \"NFATc1 siRNA knockdown, NFATc1 overexpression, TRAIL promoter reporter assay with NFAT site deletion, ChIP for Sp1 binding, Sp1 chemical inhibition and siRNA\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP for Sp1 plus promoter deletion analysis establishing indirect NFATc1-Sp1-TRAIL regulatory mechanism\",\n      \"pmids\": [\"21603612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NFATc1 activity regulates dexamethasone-induced myocilin (MYOC) expression in human trabecular meshwork cells; dexamethasone induces calcineurin-dependent NFATc1 nuclear translocation within 15 minutes in a calcium-independent mechanism, and NFATc1 siRNA knockdown reduces MYOC mRNA induction.\",\n      \"method\": \"NFATc1 siRNA knockdown, calcineurin inhibitors (cyclosporin A, INCA-6), immunofluorescence for NFATc1 nuclear translocation, ionomycin treatment control\",\n      \"journal\": \"Experimental Eye Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological inhibitors and siRNA knockdown with localization assay; calcium-independent mechanism noted\",\n      \"pmids\": [\"25450062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FOXP3 competes with NFAT1 for binding to the endogenous NFAT2 (NFATc1) promoter, suppressing NFATc1 transcription in regulatory T cells; ectopic NFAT2 expression partially restores IL-2 production in FOXP3+ Tregs, demonstrating that FOXP3-mediated repression of NFATc1 contributes to T cell anergy.\",\n      \"method\": \"ChIP for FOXP3 and NFAT1 at NFATc1 promoter, inducible FOXP3-expressing cell lines, retroviral NFAT2 overexpression, IL-2 reporter assay\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP competition assay at NFATc1 promoter with functional rescue; single study\",\n      \"pmids\": [\"19564342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cav2.2 (voltage-gated calcium channel) upregulates USP43 deubiquitinase expression through NFAT2 (NFATc1) dephosphorylation and nuclear localization, which then stabilizes cortactin to promote invadopodia formation and breast cancer metastasis.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown of Cav2.2/NFAT2/USP43, NFATc1 nuclear localization imaging, invasion assay, in vivo metastasis model\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway linking Cav2.2-NFATc1-USP43-cortactin with multiple knockdown validations; single study\",\n      \"pmids\": [\"36137995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NFATc1 drives NAFLD progression through ER stress sensing and activation of the PERK-CHOP unfolded protein response (UPR) in hepatocytes; hepatocyte-specific NFATc1 depletion prevents disease acceleration in high-fat western diet-fed mice, and NFATc1 activation induces NLRP3 inflammasome activation.\",\n      \"method\": \"Hepatocyte-specific NFATc1 conditional knockout and overexpression transgenic mice, high-fat diet model, PERK-CHOP pathway analysis, NLRP3 inflammasome activation assay, TUDCA pharmacological inhibition\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dual conditional KO and overexpression mouse models with defined ER stress pathway mechanism\",\n      \"pmids\": [\"35365570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CR3 engagement by M. leprae PGL-I activates the Syk tyrosine kinase, inducing calcineurin-dependent nuclear translocation of NFATc in innate immune cells (macrophages, neutrophils, dendritic cells), selectively augmenting production of IL-2 (DCs), IL-10 (PMNs), and IL-1β (macrophages).\",\n      \"method\": \"CR3 engagement assay, Syk kinase inhibitor, calcineurin inhibitor, NFATc nuclear translocation imaging, cytokine measurement in infected mice\",\n      \"journal\": \"Frontiers in Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection with multiple cell types and in vivo validation; single study\",\n      \"pmids\": [\"31921172\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NFATc1 is a calcium/calcineurin-regulated transcription factor whose nuclear activity is controlled by a multi-kinase phosphorylation cycle: calcineurin dephosphorylates conserved serine residues (including SP-repeat motifs) to drive nuclear import, while GSK-3, JNK, ERK, p38, CK2, and DYRK1A phosphorylate these same or adjacent residues to promote nuclear export or protein stability; in osteoclasts, RANKL-induced Ca2+ oscillations activate calcineurin-NFATc1 signaling, and NFATc1 autoregulates its own P1 promoter to amplify expression, acting as a master transcriptional regulator of osteoclastogenesis by cooperating with PU.1, MITF, c-Fos, STAT3, and AP-1 at target gene promoters (cathepsin K, OSCAR, CCR1, SLC7A11); beyond bone, NFATc1 controls cardiac valve formation (endocardial cells, calcineurin-dependent nuclear entry), hair follicle stem cell quiescence (CDK4 repression downstream of BMP), PD-1 expression in T cells, TRAIL and myocilin expression, and is subject to SUMOylation (repressing IL-2) and epigenetic regulation via SSP-derived α-ketoglutarate-dependent histone demethylation at its gene locus.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NFATc1 is a calcium/calcineurin-regulated transcription factor that integrates signal-dependent dephosphorylation with multi-kinase rephosphorylation to control gene expression across diverse developmental and homeostatic programs. Calcineurin dephosphorylates conserved serine residues to drive nuclear import and DNA binding, while GSK-3, JNK, ERK, p38, CK2, and DYRK1A phosphorylate overlapping or adjacent sites to promote nuclear export, inhibit DNA binding, or modulate protein stability [PMID:9072970, PMID:10652349, PMID:11063740, PMID:28235034]. NFATc1 functions as the master transcriptional switch for osteoclastogenesis—induced by RANKL/TRAF6/c-Fos signaling and sustained by autoregulation of its own P1 promoter—where it cooperates with PU.1, MITF, STAT3, and AP-1 to activate target genes including cathepsin K, OSCAR, CCR1, and SLC7A11 [PMID:12479813, PMID:16275763, PMID:17403683, PMID:31462535]. Beyond bone, NFATc1 is essential for cardiac valve morphogenesis through calcineurin-dependent nuclear entry in endocardial cells, maintains hair follicle stem cell quiescence by repressing CDK4, drives B-1a cell development, regulates PD-1 expression in T cells, and—when SUMOylated—represses IL-2 to shape regulatory T cell responses [PMID:9515964, PMID:18243104, PMID:14595020, PMID:18802087, PMID:32986812].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Identifying the kinase that opposes calcineurin-mediated NFATc1 activation revealed that GSK-3 directly phosphorylates conserved N-terminal serines to drive nuclear export, establishing the core phosphorylation/dephosphorylation toggle governing NFATc1 subcellular localization.\",\n      \"evidence\": \"Biochemical purification of NFATc1 kinase activity followed by in vitro phosphorylation and nuclear localization assays\",\n      \"pmids\": [\"9072970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the GSK-3 priming kinase was not resolved\", \"In vivo significance of GSK-3-mediated export not tested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Genetic knockout and structural studies simultaneously revealed that NFATc1 is essential for cardiac valve formation—acting through calcineurin-dependent nuclear translocation in endocardial cells—and that its DNA-binding domain undergoes conformational reorientation upon cooperative complex formation with AP-1.\",\n      \"evidence\": \"NFATc1 knockout mice showing lethal valve defects with cyclosporin A phenocopy; NMR solution structure of NFATc1 DBD–DNA complex\",\n      \"pmids\": [\"9515964\", \"9506523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional targets in endocardial cells were not identified\", \"Structural basis of full-length NFATc1 regulation by phosphorylation remained unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Expanding the kinase network controlling NFATc1 showed that JNK, ERK, p38, and CK2 each physically associate with and phosphorylate the N-terminal regulatory domain to block nuclear import, while GSK-3 phosphorylation was further shown to directly inhibit DNA-binding activity—not just localization.\",\n      \"evidence\": \"Co-immunoprecipitation and in vitro kinase assays with localization readouts; EMSA with GSK-3-phosphorylated NFATc1 and Ser-Pro repeat mutants\",\n      \"pmids\": [\"10652349\", \"11063740\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of individual kinases in physiological contexts undetermined\", \"Whether all kinases act simultaneously or in sequence was not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating pattern-specific nuclear translocation in adult muscle fibers established that NFATc1 decodes calcium signaling frequency, translocating only in response to slow-twitch stimulation patterns to control fiber-type gene expression.\",\n      \"evidence\": \"GFP-NFATc1 live imaging in electrically stimulated adult mouse skeletal muscle fibers with cyclosporin A validation\",\n      \"pmids\": [\"11581284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets in slow-twitch fibers not identified\", \"Mechanism discriminating stimulation frequencies upstream of calcineurin unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The discovery that RANKL induces NFATc1 via TRAF6/c-Fos and Ca²⁺ oscillation–calcineurin signaling, and that NFATc1-deficient cells cannot form osteoclasts while ectopic NFATc1 suffices, established NFATc1 as the master transcription factor for osteoclastogenesis. Concurrently, autoregulation of the P1 promoter by the short NFATc1/αA isoform was identified in T cells.\",\n      \"evidence\": \"NFATc1−/− ES cell differentiation, retroviral ectopic expression bypassing RANKL, Ca²⁺ oscillation imaging; P1 promoter reporter dissection and isoform-specific expression analysis\",\n      \"pmids\": [\"12479813\", \"12121669\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The full set of NFATc1 osteoclast target genes was not defined\", \"Isoform-specific functions beyond apoptosis resistance remained unexplored\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Establishing a cell-intrinsic requirement for NFATc1—but not NFATc2—in B-1a cell development demonstrated non-redundant roles of NFAT family members in lymphocyte lineage commitment.\",\n      \"evidence\": \"NFATc1−/− and NFATc2−/− mice, mixed-allotype chimeras, retroviral rescue, flow cytometry\",\n      \"pmids\": [\"14595020\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream target genes in B-1a cells not identified\", \"Mechanism of selective NFATc1 elevation in B-1a cells unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that NFATc1 autoregulates its own P1 promoter via tandem NFAT sites within a CpG island explained the sustained high expression unique to committed osteoclasts, and the inability of NFATc2 to substitute in vivo despite in vitro rescue capacity. Concurrently, CCR1 was identified as a direct NFATc1 target controlling osteoclast precursor migration.\",\n      \"evidence\": \"Adoptive transfer of NFATc1−/− HSCs, blastocyst complementation, ChIP/reporter for P1 autoregulation; CCR1 promoter reporter with cyclosporin A suppression and siRNA migration assay\",\n      \"pmids\": [\"16275763\", \"16355273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Epigenetic mechanism maintaining P1 CpG island accessibility not fully defined\", \"Whether CCR1 regulation requires NFATc1 co-factors was not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"ChIP at osteoclast target gene promoters revealed a sequential assembly model: MITF/PU.1 complexes pre-occupy promoters in response to CSF-1, RANKL adds p38-phosphorylated MITF and SWI/SNF, and NFATc1 is recruited last during terminal differentiation to sustain expression.\",\n      \"evidence\": \"ChIP at cathepsin K and ACP5 promoters, Co-IP of MITF/PU.1 complexes, MITF/PU.1 mouse models\",\n      \"pmids\": [\"17403683\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of factor departure from promoter upon signal withdrawal unknown\", \"Whether SWI/SNF recruitment depends on NFATc1 not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Two non-overlapping roles were established: NFATc1 directly activates PD-1 transcription in T cells by binding a novel regulatory element at the pdcd1 locus, and NFATc1 maintains hair follicle stem cell quiescence by repressing CDK4 downstream of BMP signaling.\",\n      \"evidence\": \"ChIP and binding-site mutagenesis at the pdcd1 locus with reporter assay; conditional NFATc1 ablation in skin with CDK4 reporter analysis\",\n      \"pmids\": [\"18802087\", \"18243104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-factors mediating NFATc1 repression of CDK4 not identified\", \"Whether NFATc1 regulates other immune checkpoint genes was not explored\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"FOXP3 was shown to compete with NFAT1 for binding at the NFATc1 promoter to suppress its transcription in Tregs, revealing a mechanism for Treg anergy; separately, VEGF and RANKL were found to activate NFATc1 through distinct co-signaling pathways (MEK/ERK vs. JNK) to control endocardial cushion cell proliferation versus cathepsin K induction during valve development.\",\n      \"evidence\": \"ChIP competition of FOXP3/NFAT1 at NFATc1 promoter, retroviral rescue of IL-2; NFATc1−/− mice plus chick ECC explants with pharmacological MEK/JNK/calcineurin inhibition\",\n      \"pmids\": [\"19564342\", \"19661463\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether FOXP3-NFATc1 promoter competition occurs genome-wide is unknown\", \"Quantitative contributions of MEK vs. JNK pathways in vivo not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"DYRK1A was identified as an NFATc1 kinase in osteoclasts (opposed by harmine inhibition), and NFATc1 was found to play a non-osteoclast role in epicardium-derived cells where RANKL/NFATc1 induces cathepsin K for extracellular matrix invasion during coronary vessel development.\",\n      \"evidence\": \"In vitro DYRK1A phosphorylation assay with harmine inhibition in RAW264.7 cells; conditional NFATc1 knockout in EPDCs with in vivo embryonic analysis\",\n      \"pmids\": [\"21504804\", \"21447555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific DYRK1A phosphorylation sites on NFATc1 were not mapped in this study\", \"Other NFATc1 target genes in EPDCs beyond cathepsin K not explored\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"NFATc1 was shown to form a transcriptional complex with STAT3 that drives oncogenic enhancer-promoter communications in Kras-driven pancreatic carcinogenesis; separately, STAT3 was identified as a direct transcriptional activator of the NFATc1 promoter in osteoclasts, and NFATc1 was found to create a positive feedback loop by directly activating Itpr2 transcription in cardiomyocytes.\",\n      \"evidence\": \"Co-IP of NFATc1-STAT3, ChIP in pancreatic cancer GEMMs; conditional Stat3 KO with ChIP at NFATc1 promoter and rescue; ChIP at Itpr2 promoter in calcineurin-A transgenic mice\",\n      \"pmids\": [\"24694735\", \"31462535\", \"24415751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full genome-wide NFATc1-STAT3 co-occupancy map not generated\", \"Whether Itpr2 feedback is specific to pathological hypertrophy or operates in normal physiology unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"NFATc1 was found to cooperate with Sox2 to drive EMT and cancer stemness in pancreatic cancer, opposed by p53-miR200c, and PU.1 was shown to directly transactivate the NFATc1 promoter in osteoclasts.\",\n      \"evidence\": \"Co-IP of NFATc1-Sox2 in GEMM pancreatic cancer cells with EMT assays; ChIP for PU.1 at NFATc1 promoter with siRNA/retroviral rescue\",\n      \"pmids\": [\"25586376\", \"26117255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"NFATc1-Sox2 direct versus indirect DNA co-binding not distinguished\", \"Whether PU.1 transactivation of NFATc1 is independent of autoregulatory loop not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"DYRK1A was shown to phosphorylate specific NFATc1/αA residues (S261, S278, S403, S409) that paradoxically stabilize the protein by blocking ubiquitin-proteasome degradation, contrasting its destabilizing effect on NFATc2; separately, Gα13-RhoA-Akt-GSK3β signaling was identified as a negative regulator of NFATc1 in osteoclasts.\",\n      \"evidence\": \"In vitro phosphorylation with site-specific mutants and ubiquitination assay; osteoclast-lineage Gna13 conditional KO with pharmacological epistasis\",\n      \"pmids\": [\"28235034\", \"28102206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for divergent DYRK1A effects on NFATc1 vs. NFATc2 stability unknown\", \"Whether Gα13 pathway operates in non-bone contexts not explored\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Epigenetic regulation at the NFATc1 locus was established through ASXL1 loss, which reduces H3K27me3 and increases H3K4me3 at the NFATc1 promoter via Jmjd3 histone demethylase, explaining enhanced NFATc1 expression and osteoclastogenesis in ASXL1-deficient cells.\",\n      \"evidence\": \"Conditional ASXL1 KO in myeloid cells, ChIP for H3K27me3/H3K4me3 at NFATc1 promoter, Jmjd3 siRNA rescue\",\n      \"pmids\": [\"30266822\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ASXL1-dependent epigenetic regulation of NFATc1 occurs outside the myeloid lineage unknown\", \"Full set of Jmjd3-regulated loci beyond NFATc1 not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Homer2/3 scaffold proteins were identified as Ca²⁺-independent modulators that physically interact with NFATc1 and gate its access to calcineurin; RANKL disrupts the Homer–NFATc1 interaction to enable dephosphorylation and nuclear translocation.\",\n      \"evidence\": \"Homer2/3 double KO mice, Co-IP of Homer with NFATc1 and calcineurin, Ca²⁺ oscillation measurements showing no change, cyclosporin A rescue\",\n      \"pmids\": [\"31319381\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of Homer–NFATc1 interaction not determined\", \"Whether Homer regulation applies to non-osteoclast contexts unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"SUMOylation of NFATc1 was shown to function as a post-translational switch that represses IL-2 production; preventing SUMOylation in knock-in mice elevated IL-2, expanded Tregs via STAT5/Blimp-1, and suppressed autoimmune and alloreactive responses.\",\n      \"evidence\": \"Transgenic knock-in mouse with prevented NFATc1 SUMO modification, EAE and GVHD disease models, cytokine and signaling analysis\",\n      \"pmids\": [\"32986812\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SUMO site(s) on NFATc1 and the E3 SUMO ligase were not identified in this study\", \"Whether SUMOylation affects NFATc1 function outside T cells not addressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"NFATc1 was linked to hepatic ER stress: hepatocyte-specific depletion prevents NAFLD progression by blocking PERK-CHOP UPR and NLRP3 inflammasome activation, revealing a metabolic-inflammatory role beyond its canonical immune and bone functions.\",\n      \"evidence\": \"Hepatocyte-specific NFATc1 conditional KO and overexpression transgenic mice on high-fat diet, PERK-CHOP and NLRP3 pathway analysis\",\n      \"pmids\": [\"35365570\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NFATc1 directly binds PERK or CHOP gene promoters not tested\", \"Upstream signals activating NFATc1 in hepatocyte ER stress not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Metabolic control of NFATc1 expression was established: the serine synthesis pathway generates α-ketoglutarate that fuels histone demethylases removing H3K27me3 from the Nfatc1 locus, coupling amino acid metabolism to osteoclast maturation through epigenetic derepression.\",\n      \"evidence\": \"Conditional PHGDH KO in osteoclast progenitors, ChIP for H3K27me3 at Nfatc1 locus, α-ketoglutarate supplementation rescue\",\n      \"pmids\": [\"38200114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the specific demethylase(s) acting at the Nfatc1 locus downstream of α-ketoglutarate not determined\", \"Whether this metabolic-epigenetic axis regulates NFATc1 in non-osteoclast lineages unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Despite extensive characterization of individual kinases, co-factors, and epigenetic inputs, the integrated quantitative logic by which NFATc1 integrates simultaneous phosphorylation by multiple kinases, SUMOylation, and epigenetic accessibility to produce tissue-specific transcriptional outputs remains undefined; no full-length structural model of NFATc1 in complex with calcineurin exists.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length NFATc1 structure or NFATc1–calcineurin co-structure available\", \"Quantitative model of combinatorial post-translational modification integration lacking\", \"Genome-wide map of NFATc1 occupancy across multiple cell types not generated in these studies\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3, 4]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6, 8, 9, 10, 12, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 2, 5, 7, 10, 34]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 5, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 5, 26]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 8, 10, 12, 30]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 18, 25, 39]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 13, 23, 32]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [20, 21]}\n    ],\n    \"complexes\": [\n      \"NFATc1-calcineurin\",\n      \"NFATc1-STAT3\",\n      \"NFATc1-Sox2\",\n      \"NFATc1-AP-1\"\n    ],\n    \"partners\": [\n      \"GSK3B\",\n      \"STAT3\",\n      \"SOX2\",\n      \"SPI1\",\n      \"MITF\",\n      \"DYRK1A\",\n      \"HOMER2\",\n      \"HOMER3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}